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Cancer stem cells (CSC) are rare cells within a tumor reported to be resistant to standard 
chemotherapy, which can serve to populate the bulk of a tumor with more differentiated daughter 
cells and potentially contribute to recurrent disease and metastasis.  A better understanding of 
ovarian CSC could lead to novel therapeutic approaches to specifically target CSC. We 
developed two in vivo models for the study of ovarian CSC.  We first generated a human 
embryonic stem cell derived teratoma (hESCT) tumor model, creating a human tumor 
microenvironment for CSC growth. We demonstrate that unlike other tumor models, this model 
has human tumor vessels, a critical part of the CSC niche.  These vessels express tumor vascular 
specific markers (TVMs). We showed the ability of the hESCT model, with human tumor 
vascular niche, to enhance the engraftment rate of primary human ovarian cancer stem-like cells. 
Furthermore, this model can be used to test anti-human specific TVM immunotherapeutics.  
Unfortunately, the study of human CSC can be hampered by heterogeneity of primary 
tumor samples, long requirements for tumor growth in vivo, and the need for tumor growth in 
immune-deficient mice.  We therefore evaluated CSC in a transgenic murine model of ovarian 
cancer. Using flow cytometry to characterize a cell line derived from this tumor model we 
identified that CD24+ cells have a enhanced ability to form tumor spheres, to passage, and to 
initiate tumors in vivo; hallmarks of CSC. CD24+ cells preferentially express stem cell markers 
Nanog and c-myc and demonstrate preferential phosphorylation of STAT3. Suggesting an 
important role for STAT3 in CD24+ CSC, CD24+ cells were preferentially sensitive to inhibition 
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of STAT3 phosphorylation with the JAK2 inhibitor TG101209. Finally, in vivo therapy with 
TG101209 appeared to decrease tumor metastasis and combined with chemotherapy, prolonged 
overall survival. Furthermore, preliminary data suggests a role of CD24+ cells in tumor 
migration. Combined we have characterized two distinct models for the characterization of 


















Epithelial ovarian cancer (EOC) is the most lethal gynecologic cancer in the western 
world, accounting for more deaths than endometrial and cervical cancer combined (1), and is the 
fifth leading cause of cancer-related death among women. Most patients with ovarian cancer 
present with advanced stage disease (stage III or stage IV). These patients are treated with 
surgical removal of disease plus chemotherapy, which results in a median progression-free 
survival of 16-22 months and a 5-year survival rate of 27% although better results are now being 
reported with improvements in therapy (2, 3). 
There are four major histologic types of epithelial ovarian cancer, serous, endometrioid, 
clear cell and mucinous (4, 5). The different subtypes are characterized by distinct genetic 
alterations (6). 85% of mucinous ovarian cancers have KRAS gene mutations while KRAS 
mutations are less common in clear cell, endometrioid and high grade serous carcinomas (7).  
Mutations of the CTNNB1 gene encoding ß-catenin are observed in 16-38% of ovarian 
endometrioid adenocarcinomas (OEAs) (8). With the exception of TP53, mutated in more than 
95% of serous ovarian cancers, there is no predominant mutation in serous ovarian cancers (9, 
10) (See Table 2). Recently an alternative classification of ovarian cancer has been proposed 
where it is divided into two types (11, 12). Type I EOC includes endometrioid, clear cell, 
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mucinous and low-grade carcinomas, which usually originate from precursor lesions like 
endometriosis or borderline tumors (11, 13). In contrast, type II EOC includes high-grade serous 
carcinomas that are biologically aggressive tumors with a tendency for metastasis (11, 13). Type 
I and type II ovarian cancers can have overlapping features, suggesting that a subset of EOC may 
undergo type I to type II progression along with the acquisition of somatic TP53 mutations (12, 
13).  
 
Origin of Ovarian Cancer 
It is currently debated whether the origin of ovarian cancer is in the ovarian surface 
epithelium (OSE) of mesothelial origin (14) or the fallopian tube (15). It has been proposed that 
ovarian tumorigenesis is associated with ovulation wound repair and/or inflammation, possibly 
leading to abnormal stem cell expansion in the OSE (16). The dilemma of the theory of ovarian 
cancer arising from the OSE is that there are different types of ovarian cancers based on 
histology, which are not necessarily derived from the mesothelium (17).  These subtypes have 
diverse histological origins and different clinical and pathological behaviors. Therefore, it is 
unlikely that all these tumors originate from the same cell or the same lesion (18).  Recently it 
has been proposed that migratory cancer cells may come from the fallopian tube or from other 
sites from the female reproductive tract and travel through the fallopian tubes and arrive to the 
OSE (12, 18, 19).  
In addition to the exact tissue of origin regarding cancer, further controversy exists 
regarding specific cell type which leads to tumor initiation. It has been proposed that specifically 
normal stem cells which incur genetic and epigenetic changes can become cancer stem cells 
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(CSC) to initiate tumors.  Alternatively, it is possible that non-stemlike cells can gain stem cell 
like functions via genetic changes. 
 
 
Ovarian Cancer Stem Cells 
The majority of ovarian cancer patients achieve complete clinical remission following 
initial treatment. Unfortunately, most will relapse and succumb to their disease. This is consistent 
with the cancer stem cell hypothesis, which theorizes that within a heterogeneous population of 
cancer cells, rare chemotherapy-resistant cells with stem cell like qualities can serve to populate 
the bulk of a tumor with more differentiated daughter cells and potentially contribute to recurrent 
disease (20, 21).  In the past five years a significant amount of work has been done to identify 
ovarian cancer cells with characteristics of stem cells (22-31).  
Within an ovarian cancer, all tumor cells are not equal; tumor cells display a great deal of 
heterogeneity.  More specifically, within a given tumor (or even tumor cell line), there are 
abundant distinct tumor cell populations expressing different markers.  These unique cell 
populations have differential capacities for growth, survival, metastasis and resistance to 
chemotherapy and radiation therapy.  Cancer stem cells make up a small proportion of malignant 
cells within a tumor, typically 0.01-1%.  Cancer stem cells have the capacity to undergo either 
symmetric or asymmetric divisions to recreate a tumor with the complete original complex pool 
of tumor cells in immune-suppressed mice (32, 33). Moreover, these highly specialized cell 
populations reportedly have unlimited division potential and therefore are capable of serial 
passages in vitro and in vivo.  These cells have been termed cancer stem cells (CSC), tumor 
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initiating cells (TICs), cancer initiating stem cells (CIC) and tumor propagating cells (TPC). For 
the purpose of this thesis dissertation we will refer to these cells as CSC.  
Ovarian CSC are, for the most part, shown to be resistant to chemotherapy and radiation 
therapy (22, 27, 29, 34).  Based on their resistance to traditional cancer therapies and presumed 
ability to recapitulate the original tumor, CSC are believed to be the source of recurrent ovarian 
cancer.  Consequently, there is a strong interest to identify, functionally characterize the 
pathobiology of, and eventually target ovarian CSC.  To date, the study of CSC in ovarian cancer 
has been extremely challenging for several reasons, patient-to-patient heterogeneity, long 
requirements to grow and the use of immunosuppressed mice. It has been postulated that CSC 
may arise from genetic changes in normal stem cells (28, 35).  Thus, one way to identify CSC is 
to characterize cells within a tumor that express known stem cell markers for the tissue of origin. 
There are several ovarian CSC markers that have been previously reported in the last five years.  
 
CD24 
CD24 is a P-selectin ligand for human tumor tissue, also known as a heat-stable antigen. 
It is a glycoprotein that is expressed in neutrophils, B cells, immature thymocytes, and red blood 
cells (36). CD24 was initially detected in hematologic cancers such as leukemia and lymphoma, 
and later found to be overexpressed in solid tumors such as small cell lung carcinoma and 
ovarian cancer (37-39). CD24 is expressed on the cancer cell surface, and is a cell adhesion 
molecule that binds to P-selectin on platelets or vascular endothelial cells to promote cancer 
metastasis (40), suggesting CD24 may play a role in tumor progression. CD24 has been 
identified as a CSC marker in pancreatic (41) and liver cancers (42). Interestingly, in breast 
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cancer, CSC are reported to be CD24- or CD24dim. The differences in CD24 expression in 
different CSC may relate to the different tissues of origin.   
Ovarian cancer patients whose tumors have a high level of CD24 expression have high 
grade tumors with poorer prognosis and shorter survival times (36). Gao et al. recently reported 
CD24 as a putative CSC marker in ovarian cancer.  They established primary ovarian cancer cell 
lines from serous and mucinous cystadenocarcinomas and found that cells with the CSC 
characteristics of quiescence, chemoresistance, and tumor initiation capacity were enriched for 
CD24 expression (26). CD24+ cells expressed stemness related genes such as Nestin, ß-catenin, 
Bmi-1, Oct4, Oct3/4, Notch1, and Notch4 when compared to CD24- cells. Interestingly, they 
found expression of both CD133 and CD117 in the majority of CD24+ cell clones generated. 
Approximately 1% of CD24+ cells co-expressed CD133 and approximately 1% of CD24+ cells 
co-expressed CD117.  More recently, this same group analyzed cell clones generated from cells 
located in the center of a tumor and cells at the tumor periphery (43).  They hypothesized that 
cells at the tumor’s leading edge would be enriched for CSC.  They found that cells from the 
leading edge had a higher proportion of side population cells (43). Side population (SP) cells are 
defined by Hoechst dye exclusion in flow cytometry, are enriched by stem cell markers and are 
believed to be chemo-resistant (44). Within the SP cells they found enriched expression of CD24 
and CD117.  Once again approximately 1% of cells co-expressed CD24 and CD117.  
Unfortunately, the tumorigenicity of these cells was not assessed.   
CD24 expression in combination with CD44 and the epithelial cell adhesion molecule 
(EpCam) was also assessed in conjunction with SP cells (45).  In established cell lines OVCAR-
3, SKOV-3 and IGROV-1 treated with chemotherapy, the percentage of cells expressing all three 
cell surface markers was found to increase.  In addition, when compared to CD24-, CD44-, 
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EpCam- cells, these ‘triple positive’ cells demonstrated greater invasion into matrigel and more 
rapid tumor growth in vivo.  This triplet of markers was not functionally assessed in human 
tumors. 
Interestingly, CD24 has been reported to promote self-renewal through STAT3 and 
Nanog signaling in liver cancer (42). In ovarian cancer, CD24 and Nanog have been shown to 
co-localize in the ovarian surface epithelium and premalignant cysts (46). Schreiber et al. 
showed that higher the malignancy of ovarian cancer higher the percentage of co-localization of 
Nanog and CD24 in premalignant cysts, which have been proposed as one of the sites that may 
cause ovarian cancer. Briefly they mentioned that in benign ovarian tumors 37% of specimens 
were positive to CD24 and Nanog labeling with 26% of CD24+ cells localized in cyst walls. In 
contrast, 79% of serous borderline tumors were positive for CD24 and 42% were localized in 
cysts walls. 32% of CD24+ cells showed co-localization Nanog. In serous ovarian carcinomas 
81% of specimens were labeled with CD24 antibodies and 45% of CD24+ cells co-localized with 
Nanog (46). These findings may be relevant to ovarian cancer since it can be utilized for its early 
detection and may indicate a relationship to the source of this disease.  
 
CD133 and Aldehyde Dehydrogenase 
One of the most widely described ovarian CSC markers is CD133.  CD133 or Prominin is 
a membrane glycoprotein encoded by the CD133/Prom-1 gene. It was first detected as a marker 
of hematopoietic stem cells and since then has been demonstrated to be a marker of numerous 
normal and cancer stem cell populations (47-53).  In one of the first indications that CD133 may 
be a marker of ovarian CSC, Ferrandina et al. analyzed expression of CD133 in 41 ovarian 
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tumors, 8 normal ovaries, and 5 benign ovarian tumors (54).  They found that primary ovarian 
cancer CD133+CK7+ cells had greater colony forming potential and had a higher proliferative 
potential than CD133- CK7+ cells (55). Interestingly, they also found that normal ovaries and 
benign tumors had significantly lower expression of CD133 than ovarian carcinomas (55).  In 
one of the first functional characterizations of CD133 as an ovarian CSC marker, Baba and 
colleagues demonstrated that CD133+ cells from established cell lines had greater tumor 
initiating capacity than CD133- cells (22).  Similarly, consistent with a CSC phenotype, CD133+ 
cells demonstrated greater resistance to chemotherapy.  They also reported that CD133 
expression in tumor cells was regulated at the level of promoter methylation, suggesting that 
epigenetic events could be responsible for the induction of tumor ‘stemness’.   
The study by Baba and colleagues relied primarily on established cell lines.  Curley et al. 
used an alternate approach to study CSC in primary human tumor samples (25).  They 
established 11 primary xenografts from freshly isolated human ovarian carcinomas and then 
characterized the ability of different cell populations derived from the primary xenografts to 
initiate new tumors and their ability to continue to undergo serial passages in 
immunocompromised mice.  For both serous and clear cell ovarian cancers, the CD133+ high 
expressing cell fraction demonstrated greater tumor initiating capacity than CD133- cells. In 
addition CD133+ cells gave rise to CD133- cells and a tumor with histologic characteristics of the 
primary tumor.  In one instance a 99% pure CD133- fraction gave rise to a tumor, albeit with a 
much longer latency period. However an interesting point was the resulting tumor had just over 
10% CD133 positive cells suggesting that either CD133- cells can become CD133+ cells or the < 
1% CD133+ fraction was sufficiently amplified to become 10% of the resulting tumor.  
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Finally, our group and one other group recently analyzed the combined expression of 
CD133 and the stem cell marker aldehyde dehydrogenase (ALDH) as ovarian CSC markers (29, 
56).  We found that in cell lines and primary human ovarian tumors in which tumor cells lacked 
CD133 expression, FACS isolated ALDH+ activity cancer cells were capable of initiating tumors 
in mice whereas limiting dilutions of ALDH- activity cells were not. This is in accordance with 
the work of Landen and colleagues demonstrating specifically ALDH1A1+ cells are ~50 fold 
more tumorigenic than ALDH1A1- cells (27). In established cell lines and primary human 
tumors in which tumor cells expressed CD133, CD133+ALDH+ (or CD133+ cells with ALDH 
activity) cells had far greater tumor initiating capacity and shorter tumor latencies than CD133-
ALDH- cells.  Interestingly, while CD133+ALDH- cells isolated from cell lines were highly 
tumorigenic, CD133+ALDH- cells isolated from primary tumors were unable to initiate tumors in 
immunocompromised mice. Whether these cells truly have restricted tumor initiating capacity, or 
are more sensitive to isolation procedures remains to be determined. Both ALDH+ activity CSC 
and CD133+ALDH+ human ovarian CSC were highly angiogenic.  This is consistent with studies 
suggesting ovarian CSC from tumor metastases are capable of attracting endothelial progenitors 
to promote angiogenesis (57).   
 
CD44 and CD117 
CD44 is the receptor of hyaluronate and has been identified as a marker of CSC in breast 
(58), prostate (50), colorectal (59), pancreatic (41), and head and neck squamous cell carcinomas 
(60). CD117, also known as c-kit, is another well-characterized stem cell marker, which has been 
implicated as a CSC marker in several solid tumors. In the first study to consider ovarian CSC, 
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Szotek and colleagues use hoechst dye exclusion to identify side-population (SP) cells with CSC 
characteristics within a murine ovarian cancer cell line. These SP cells were enriched for CD117 
expression. However, they found human ovarian cancer ascites SP cells lacked CD117 
expression.  In contrast, Bapat et al. isolated tumor cells from the ascites of a patient diagnosed 
with serous ovarian cancer and established 19 spontaneously immortalized clones (23).  
Molecular characterization of these clones identified the expression of CD44, CD117, and scatter 
factor - the ligand for CD117. Interestingly, only one of these clones demonstrated 
tumorigenicity in vivo, suggesting the presence of cells with different tumor initiating capacity 
within the ovarian tumor associated ascites.  Alternatively, one could speculate this clone had 
acquired additional genetic changes due to in vitro culture.  Consistent with this, a second clone 
underwent spontaneous transformation during culture. 
Similarly, Zhang et al. analyzed tumor spheroids generated from the ascites of 5 patients 
with serous ovarian cancer (31).  After approximately ten serial passages in a stem cell based 
media (lacking serum and addition of growth factors such as FGF, EGF and other factors such as  
insulin, hydrocortisone and ß-mercaptoethanol) they observed that the remaining spheroid cells 
were highly enriched for CD44 and CD117 expression.  Like the studies above for CD133 (22, 
29), CD44+CD117+ spheroid cells were resistant to chemotherapy, and were able to initiate and 
serially propagate tumors in mice.  Finally, using primary tumor xenografts similar to the CD133 
study above (25), Luo et al. reported that tumorigenic CD117+ lineage cells were isolated from 3 
of 14 tumor xenografts.  These cells were capable of serial transplantation and asymmetric 
division, and the presence of these cells was correlated with chemoresistance (61). 
Subsequently, Alvero et al. analyzed epithelial ovarian tumors from 147 patients prior to 
chemotherapy and found that all had a subset of CD44 positive cells, and the expression of CD44 
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was higher in metastatic tumors and tumor ascites (24). They then generated primary cell lines 
from human tumors or ascites and then injected CD44+ cells from the lines into 
immunocompromised mice.  They found that CD44+ cells recapitulated the original tumor and 
were able to undergo multiple passages in vivo (24). Complicating the interpretation of this 
study, they injected a large number of cells (1x106) and they did not test the tumorigenicity of 
CD44- cells.  Expression analysis of CD44+ and CD44- cells revealed that Myeloid 
Differentiation Factor 88 (MyD88), an activator of the NFkB signaling pathway, was 
upregulated by 10 fold in CD44+ cells, potentially linking CD44 expressing cells and chronic 
inflammatory responses of cancer (24). In a follow-up study, the same group showed that 
xenograft tumors derived from CD44+ cells gave rise to human CD34 expressing blood vessels, 
suggesting that these tumor cells have the potential to differentiate into vessels or direct other 
cells for the formation of vessels (62). Finally, a study performed using vital dyes to identify 
‘label retaining cells’ i.e. quiescent CSC, demonstrated that nearly 100% of the label retaining 
cells were CD44+CD117+ (63).  However, this study was performed with a murine tumor cell 
line so the applicability to human cancer remains uncertain.  
 
Using Novel Models to Study Ovarian Cancer Stem Cells 
The study of human ovarian cancer stem cells has been hampered by low engraftment 
rates and long requirements for tumor growth in mice. During the past five years only three 
groups could grow primary ovarian cancer stem cells in a xenograft (25, 29, 64). Other groups 
used primary tumor spheres, metastatic tissue and cell lines due to the difficulty of primary 
tumor cells to engraft in the mouse (see Table 1). Therefore new models are necessary for the 
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study of human ovarian cancer stem cells. We propose to study ovarian cancer stem cells in two 
new models.   
Cancer Stem Cells and the Tumor Microenvironment 
Within the adult organism, stem cells reside in defined anatomical microenvironments 
called niches. These architecturally diverse microenvironments serve to balance stem cell self-
renewal and differentiation (65). The same concept can be applied to the tumor 
microenvironment, which is a complex network of different cell types, soluble factors, signaling 
molecules and extracellular matrix components, which orchestrate the fate of tumor progression 
(66).  In the tumor microenvironment, CSC receive growth factor and cytokine cues from tumor 
cells, stroma and vasculature to self-renew, differentiate, induce epithelial-mesenchymal 
transition (EMT) or simply remain quiescent.  Unfortunately, the study of CSC has been 
hampered by the difficulty of these cells to engraft in mouse xenografts. Engraftment rates of 
primary cells are ~40%.  These low engraftment rates might be due to the difference of species 
and the lack of survival cues coming from the human microenvironment. In addition primary 
CSC xenografts can take up to 9 months to grow (29), which is both impractical for most studies 
and can be complicated by spontaneous tumors, which can develop in immunosuppressed mice.  
 
Studying Human Ovarian Cancer Stem Cells in a Human Microenvironment 
Several models have been developed to study cancer cell characteristics such as 
proliferation, migration, invasion, neoangiogenesis and metastasis. These include in vitro model 
systems to grow cell lines and primary cells in tissue culture plates, anchorage-independent 
systems, transwell culture systems, and 3D culture systems. The majority of in vivo model 
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systems involve the injection of tumor cells at various sites into immunocompromised mice. 
However these models all lack a human microenvironment. One of the factors within the 
microenvironment that these models lack is human tumor endothelial cells, a critical component 
of the CSC niche.  
Human brain CSC have been shown to grow near the tumor vasculature (67) where 
human endothelial cells provide secreted factors that maintain these cells in a self-renewing and 
undifferentiated state. Other studies have shown that when human brain CSC are 
xenotransplanted orthotopically, they grow near the murine vasculature (68).  In order to 
understand the interaction of CSC with the tumor microenvironment, it is necessary to study 
human CSC in a human tumor microenvironment in the mouse. Several techniques have been 
proposed with the goal of recreating a human microenvironment in the mouse with human 
vessels. One approach is the use of primary xenografts that contain tumor cells. For example, 
human renal cell and prostate carcinoma primary xenografts established from biopsy have 
previously been shown to contain human vessels even one month after implantation (69). 
However, studies with colorectal cancer biopsy xenografts have shown a rapidly replacement of 
human vessels with their murine counterparts by nearly 50% by day 10 after implantation (70).  
Stable and functional human blood vessels can be engineered in immunodeficient mice 
after co-implantation of primary human endothelial cells and human mesenchymal stem cells 
(71-73) or spheroid-based endothelial cell transplantation (74). The human vasculature 
constructed under these conditions was found to be similar to normal vessels at both the 
molecular and cellular levels. However, these tumors still lack total recapitulation of the tumor 
microenvironment. Co-injection of human endothelial cells with tumor cells has been studied by 
us (unpublished data) and others (75) and still is not an accurate substitute of the tumor 
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microenvironment. Interestingly, Alonso-Camino et al. showed that when tumor cells were co-
injected with human endothelial cells and mesenchymal stem cells in mice that underwent 
sublethal whole-body exposure to radiation, human vessels were maintained within the tumor for 
30 days before the murine vasculature reconstitutes the tumor vasculature (76). Additionally, the 
same group showed that the former mentioned organoids with human blood vessels formed by 
co-injection of human endothelial cells plus mesenchymal stem cells are appealing to human 
breast cancer circulating cells (77).  
The human vasculatures engineered in the previous models are similar to normal 
vasculature. However, several studies have shown that tumor vasculature is different from 
normal vasculature in colon (78), breast (79, 80), brain (81), and ovarian (82, 83) cancers. 
Furthermore, these studies have shown that there are tumor specific differences among tumor 
endothelial markers. Tumor growth depends on the tumor vasculature (84, 85). Tumor 
vasculature is derived from the formation of new vessels (angiogenesis), modification of existing 
vessels or recruitment and differentiation of endothelial precursors from bone marrow 
(vasculogenesis), all of which contribute to vascular heterogeneity in and among tumors (86).  
Another widely used technique to create a human microenvironment in the mouse is the 
use of human mammary fat pads to grow human breast CSC (87). Kupperwasser et al. first 
developed this technique for xenotransplantation of normal mammary epithelial cells. This 
consists of clearing fat pads of pre-pubescent mice and then replacing them by injecting a 
mixture of irradiated and non-irradiated immortalized human fibroblasts (88). The irradiated 
fibroblasts support the growth of normal and cancer epithelial cells by secreting a number of 
growth factors, collagen and possibly directly interacting with the epithelial cells (87, 89). The 
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use of human mammary fat pads in the mouse partially recapitulates a human microenvironment 
orthotopically and allows the engraftment of breast CSC.  
Another technique to create a human microenvironment in the mouse is the use of human 
embryonic stem cells (hESC), as these cells have been shown to form a teratoma if injected in 
immunosuppressed mice (90). Human embryonic stem cell derived teratoma (hESCT) is a 
benign tumor containing the three germ layers including human vessels. It has been previously 
shown hESCT can support the growth of human tumor cells (91, 92) and interestingly tumor 
cells are found near hESCT-derived vessels (93). The same group also demonstrated that hESCT 
supported the growth of primary ovarian cancer ascites (94). Primary tumor cells injected 
subcutaneously took 45-65 days to form a tumor, whereas primary tumor cells took 21-24 days 
to grow within the teratoma. Furthermore, tumors growing within hESCT showed more obvious 
differentiated glandular structures similar to the original cancer histology as compared with 
standard xenograft tumors (94). The investigators were able to identify the growth of primary 
ovarian cancer clear cell carcinoma stem cells intra-hESCT using the CSC markers CD44 and 
ALDH (95). These studies suggest a human microenvironment in the mouse will better support 
CSC growth.  
 
Mouse Model to Study Ovarian Cancer Stem Cells 
Given current deficits in the study of human CSC; poor engraftment rates, slow tumor 
growth, significant interpatient heterogeneity, and the need to grow cells in an immune-
suppressed background, murine models offer an appealing alternative approach to study CSC.  
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However, before these models can be used to study CSC, CSC need to be defined in these 
models.   
Investigators have attempted to create mouse models of human ovarian cancer by 
introducing the common genetic alterations of this disease into mice. The generation of 
genetically engineered mouse models of ovarian cancer in which the fallopian tube or the OSE is 
specifically targeted has been hampered by the lack of defined transcriptional promoters active 
specifically in these cell types (96). Specifically, promoters used to express genes in OSE are 
also active in other tissues of Mullerian origin (fallopian tube, uterus, cervix and ovarian 
granulosa cells) (96). Cre-Lox system has been used to induce targeted deletion of tumor 
suppressor genes and to activate oncogenes. The Cre-Lox system consist of a single enzyme, Cre 
recombinase that recombines a pair of short target sequences called the Lox sequences. Placing 
Lox sequences appropriately allows genes to be activated, repressed, or exchanged for other 
genes. For example, the Mullerian inhibiting substance II receptor (MISRII) promoter drives 
transgene expression in the OSE and ovarian granulosa cells, but is also expressed in the 
mesenchyme of the oviduct (96). One mouse model utilized the MISRII promoter to drive 
expression of the SV40 large T antigen (SV40-Tag), which is a viral oncogene that binds to and 
inactivates TP53 and retinoblastoma (Rb), both of which are altered in ovarian cancer (96-98). 
However, only 50% of the mice in this model system developed large undifferentiated ovarian 
adenocarcinomas and took 90-100 days for tumors to form (97).  
Adenoviral vectors that express Cre recombinase can be used to selectively express or 
delete genes in the ovary, by injecting the vector into the ovarian bursa. This theoretically results 
in the Cre-expressing adenovirus only reaching oviductal, ovarian surface epithelial and bursa 
	  
16	  
cells. However, in practice they sometimes leak out through the injection site and reach uterine 
tissue.  
The BRCA1 and 2 genes are either mutated or silenced by methylation in approximately 
20% of all high-grade ovarian cancers and approximately 95% harbor TP53 mutations (10). Loss 
of BRCA1 in combination with TP53 (BRCA1LoxP/LoxP TP53LoxP/LoxP ) mice developed 
leiomosarcoma but not serous ovarian cancer (99). Mice with MISRII-Cre; Ptenfl/fl; Dicerfl/fl 
developed tumors resembling high-grade serous ovarian cancer in the mesenchyme of the 
oviduct that metastasized to the peritoneum and formed ascites (100). However the tumors did 
not have mutations in BRCA and TP53, which are features of high grade serous ovarian cancer.  
Wu et al. developed a mouse model that resembles human endometrioid adenocarcinoma 
with conditional inactivation of the APC and PTEN tumor suppressor genes (101). This mouse 
model belongs to the type I ovarian cancer tumor classification (for reference to type I and type 
II ovarian cancers see page 2 on the ovarian cancer section of this dissertation document).    
Recently, Wu et al. developed a new mouse model of ovarian cancer with conditional 
inactivation of the APC and PTEN tumor suppressors with the addition of TP53 deletion, 
resulting in a more aggressive phenotype, shortened survival and more widespread metastasis 
(like type II ovarian cancers) (13). This new model is more applicable to the majority of ovarian 
cancer patients, which have a type II ovarian cancer disease than their previous mouse model 
with only APC and PTEN somatic mutations, which resembles human endometrioid 
adenocarcinoma (more like type I ovarian cancers) (101). In this newest mouse model of ovarian 
cancer, tumors develop following injection of adenovirus cre recombinase (AdCre) into the 
ovarian bursa of Apcflox/flox; Ptenflox/flox ; TP53 flox/flox mice at 8-10 weeks of age (13). These mice 
developed metastases in locations similar to those seen in patients with stage IV ovarian cancer, 
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and show similar morphology, biological behavior and gene expression patterns to their human 
counterpart (13). 76% of mice develop ascites. This mouse model is an excellent tool to study 
ovarian cancer since tumors formed as early as 6 weeks following AdCre injection. Importantly, 
these mice are immunocompetent. Therefore we can analyze the possible effects of the tumor 
microenvironment on therapeutic response.  
 
Ovarian Surface Epithelium Stem Cells 
The origin of CSCs is not known. Potentially CSC could originate from normal stem cells 
that acquired mutation over time. Surprisingly few studies have been performed characterizing 
normal epithelial ovarian stem cells. The first attempt to identify a stem cell population in murine 
OSE was reported by Szotek et al. Using BrdU and histone2B-GFP transgenic mice they 
identified a population of label retaining cells in the OSE which was quiescent and enriched in 
the Hoechst stain ‘side population’ (102). More recently, a population of murine OSE cells in the 
hilum between the ovary and oviduct were found to be responsible for repopulation of the OSE 
(103). These cells were were found to be relatively quiescent, and expressed the stem cell 
markers ALDH, CD133 and LGR5 (103). Importantly, when TP53 and Rb1 mutations were 
introduced into these cells, two relevant mutations in human ovarian cancer, these cells had 
increased tumor initiation capacity. These studies suggest that there may be a murine OSE stem 
cells that when mutated act as CSC. However, more detailed studies remain to be carried out to 





Ovarian	  cancer	  stem	  cell	  studies	  have	  been	  hampered	  by	  patient	  heterogeneity,	  low	  
engraftment	  in	  mice,	  long	  requirements	  for	  tumor	  growth	  and	  the	  use	  of	  
immunosuppressed	  mice.	  	  We	  developed	  two	  distinct	  murine	  tumor	  models	  to	  study	  
ovarian	  cancer	  stem	  cells.	  One	  model	  expands	  the	  human	  ESCT	  model	  to	  generate	  
confirmed	  human	  tumor	  vessels	  recreating	  the	  human	  tumor	  microenvironment	  for	  human	  
primary	  ovarian	  cancer	  stem	  cells	  to	  engraft.	  Another	  model,	  which	  we	  know	  its	  genetics	  
deficits,	  therefore	  making	  it	  homogeneous,	  provides	  rapid	  tumor	  growth	  and	  importantly	  
offers	  an	  immunocompetent	  microenvironment.	  With	  both	  of	  these	  models	  we	  can	  test	  













Table 1.  Previously published ovarian cancer stem cell markers 
Marker Source of ovarian CSC injected in xenografts 
CD44 Primary cancer cell lines and spheres (24) 
CD117 and CD44 Primary spheres (31) 
CD133 Cell line (22), Primary tumor cells (25) 
ALDH Cell line (104), Omental metastasis bulk tissue 
(27) 
ALDH and CD133 Primary tumor cells (29) (64) 
CD24 Primary patient clones passaged (cell line) (26) 
Sox2 Cell line (105) 
ALDH and Side population Cell line (106) 
 
Table 2. Prevalence of histologic types of epithelial ovarian cancer and their associated 
molecular genetic changes (adapted from Kurman et. al)(12).  
Ovarian Cancer Type Histology Frequent 
mutations 
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Human tumor vessels express tumor vascular markers (TVMs), proteins that are not 
expressed in normal blood vessels. Antibodies targeting TVMs could act as potent therapeutics.  
Unfortunately, preclinical in vivo studies testing anti-human TVM therapies have been difficult 
to perform due to a lack of in vivo models with confirmed expression of human TVMs.  We 
therefore evaluated TVM expression in a human embryonic stem cell derived teratoma (hESCT) 
tumor model previously shown to have human vessels. We now report that, in the presence of 
tumor cells, hESCT tumor vessels express human TVMs.  The addition of mouse embryonic 
fibroblasts and human tumor endothelial cells significantly increases the number of human tumor 
vessels. TVM induction is mostly tumor type specific with ovarian cancer cells inducing 
primarily ovarian TVMs while breast cancer cells induce breast cancer specific TVMs.  We 
demonstrate the utility of this model to test an anti-human specific TVM immunotherapeutics; 
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anti-human Thy-1 TVM immunotherapy results in central tumor necrosis and a three-fold 
reduction in human tumor vascular density.  Finally, we tested the ability of the hESCT model, 
with human tumor vascular niche, to enhance the engraftment rate of primary human ovarian 
cancer stem-like cells (CSC). ALDH+ CSC from patients (n=6) engrafted in hESCT within 4-12 
weeks whereas none engrafted in the flank.  ALDH- ovarian cancer cells showed no engraftment 
in the hESCT or flank (n=3). Thus this model represents a useful tool to test anti-human TVM 





















The tumor vasculature expresses numerous genes not expressed in normal vasculature 
(78, 107-110). This is in part due to the increased expression of genes associated with 
physiologic angiogenesis, as many tumor vascular antigens are also upregulated in angiogenic 
tissues (78, 111, 112). However, if the angiogenic signature is the primary difference between 
tumor vasculature and normal vasculature, one might anticipate a significant overlap between 
vascular profiles of different tumor types. Indeed this is not the case; the vascular expression 
profile of different tumor types appears to be distinct (81, 83, 108, 110, 112, 113). This is 
consistent with murine studies suggesting physiologic and pathologic angiogenesis have distinct 
gene signatures (111), and indicates that the influence of the cancer cell on the tumor 
microenvironment may play a role in the induction of tumor specific vascular proteins. 
Tumor vascular markers (TVMs), antigens specifically expressed in tumor vessels and 
not expressed in normal vessels, represent a potentially important therapeutic target.  In 
particular, those with extracellular exposure are ideal targets for immunotherapeutics (107, 113-
115). As therapeutic targets, TVMs would be accessible to drug, and the restricted nature of 
TVM expression should limit therapy-associated side effects on normal tissues. Proof-of- 
principle studies in rodents demonstrated the potency of tumor vascular targeted therapy. 
Immunotherapeutics targeting a tumor vascular specific splice variant of fibronectin 
demonstrated profound restriction of tumor growth (116). More recently, antibodies targeting the 
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anthrax receptor (Tem8) have been shown to specifically inhibit pathologic angiogenesis, and 
restrict tumor growth (117, 118). Phase I clinical trials using an immunotherapeutic targeting the 
TVM FOLH1 suggest anti-tumor vascular immunotherapeutics are safe and potentially 
efficacious (119).  
Broader development of anti-TVM therapies has been hindered by the absence of an 
experimental system with confirmed human TVM expression with which to test potential 
therapies. Most mouse tumor models generate murine vessels and therefore cannot be used to 
test antibodies specific to human antigens. While models of human tumor vasculature have been 
proposed, these models have been difficult to reproduce, have limited long term viability, and/or 
do not have confirmed expression of TVMs (70, 120, 121).  
Beyond their role in providing nutrients to the tumor, tumor vascular cells are also a 
critical host component of the cancer stem-like cell (CSC) niche. Vascular cells receive 
angiogenic cues from CSC and in turn provide CSC with critical survival, proliferation, and 
differentiation signals (67). Thus a model with robust human tumor vasculature could enhance 
the in vivo study of human CSC, which have been surprisingly difficult to engraft in mice. The 
difficulty engrafting human CSC in mice could be related to differences in the murine and 
human microenvironments, including the vasculature.  
In the current study we focused on detailed characterization of the vasculature using the 
previously reported human embryonic stem cell teratoma (hESCT) tumor model previously 
demonstrated to have human vessels (92, 93). This model has the ease of standard xenograft 
models, however tumor vessels are derived from the human ESC and are therefore of human 
origin. It had not been clear if these are ‘normal’ human vessels or true ‘tumor vessels’ that 
express TVMs. Here, we demonstrate that, when injected with cancer cells, hESCT have vessels 
	  
31	  
expressing human TVMs. With the addition of mouse embryonic fibroblasts and primary tumor 
vascular cells, ~80% of the vessels in the tumor are human in origin and persist for up to 12 
weeks.  Using hESCT ovarian cancer and breast cancer models, we found that several TVMs are 
induced in a tumor specific fashion.  We then used this model to demonstrate the ability to test 
the therapeutic activity of anti-human tumor vascular specific antibody therapeutics; an anti-
THY1 immunotoxin delayed tumor growth and resulted in central tumor necrosis. Finally, we 
demonstrated that this tumor model, with a human microenvironment, enhances the engraftment 


















MATERIALS AND METHODS 
Cell Culture 
Use of hESC was approved by the University of Michigan Embryonic Stem Cell 
Research Oversight Committee. H9 hESC (WiCell Research Institute, Madison, WI) and H7-
GFP hESC (a gift from Joseph Wu, Stanford University) were grown as previously described 
(122). Undifferentiated ESC colonies were initially passaged by manual dissection with final 
passages performed with enzymatic digestion using TrypLE Select (Invitrogen, Carlsbad, CA). 
Human ovarian cancer cell line HEY1 and SKOV3 (American Type Culture Collection, 
Manassas, VA) were grown in RPMI containing 10% FBS. The breast cancer cell line MCF7 (a 
gift from Dr. Max Wicha, University of Michigan) was grown in MEM containing 10% FBS and 
0.01 mg/ml bovine insulin (Invitrogen, Carlsbad, CA). In order to create DsRED expressing 
cells, both MCF7 and HEY1 cells were transduced with DsRED expressing lentiviral construct 
(provided by the UMCC Vector core).    
 
In vivo Tumor Models 
NOD/SCID mice (Charles River, Wilmington, MA), were housed and maintained in the 
University of Michigan Unit for Laboratory Animal Medicine. All studies were approved by the 
University Committee on the Use and Care of Animals. hESCT were generated as previously 
described (92, 93, 122). Briefly, H9 hESC were cultured on mouse embryonic fibroblasts 
(MEFs), manually dispersed and passaged. Approximately 5x105 undifferentiated H9 hESC or 
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H7-GFP ESC were injected subcutaneously into the axilla of NOD/SCID mice (with or without 
MEFs) with 100 µl of PBS and 200 µl of matrigel (BD Biosciences, San Diego, CA). Once 
hESCT were palpable, tumor cells in 40 µl of PBS were injected intra-hESCT. 2x105 tumor cells 
(HEY1-DsREd or MCF7 DsRED) were injected alone or with 5,000 VE-Cadherin+ primary 
human tumor vascular cells (isolated as previously described) (112). For hESCT injected with 
primary ovarian CSCs, 700 (n=2), 5000 (n=3), or 10,000 (n=3) primary ALDH+ ovarian cancer 
cells (from 6 different patients) or 10,000 ALDH- cells from paired samples were injected (n=3).  
All tumor were harvested when hESCT-tumor volumes were ~2000 mm3 (range 4-12 weeks, 
median 8 weeks). For flank xenografts, 5x105 cells were injected in 100 µl of PBS and 200 µl of 
matrigel into the axilla of NOD/SCID mice. Tumors were imaged using bio-fluorescence 
(Xenogen IVIS 2000, Caliper Life Sciences, Hopkinton, MA. Murine tumors were 
APC/PTEN/p53 mutant mouse ovarian tumors (a gift from Dr. Kathy Cho, University of 
Michigan) (101, 123). 
 
Isolation of Cancer Stem Cells from Primary Ovarian Cancer Specimens 
Informed written consent was obtained from all patients before tissue procurement. All 
studies were performed with the approval of the Institutional Review Board of the University of 
Michigan. All tumors were from patients with stage III or IV epithelial ovarian or primary 
peritoneal cancer. Tumors were mechanically dissected into single-cell suspensions, red cells 
lysed with ACK buffer, and cell pellets were collected by centrifugation. CSC were then isolated 
from primary ovarian tumor single cell suspensions using the ALDEFLUOR assay fluorescence 
activated cell sorting (FACS) as previously described (29). Gating was established using 
propidium iodide (PI) exclusion for viability. ALDH/DEAB treated cells were used to define 
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negative gates. FACS was performed using the BD FACSCanto II or FACSAria (Becton 
Dickinson) under low pressure in the absence of UV light.  
 
Immunofluorescence (IF) and Immunohistochemistry (IHC) 
8 µm sections from fresh frozen tumors were fixed in acetone for 10 min and then 
washed with PBS and blocked for 20 min. Primary antibody was incubated for 2 hr, washed with 
PBS and incubated with secondary antibody for 1 hr. For IF, slides were washed with PBS and 
then mounted with Vectashield Mounting Medium for fluorescence with DAPI H-1200 (Vector 
Laboratories, Burlingame, CA). Antibodies used for IF and IHC are listed in Supplementary 
Table 1. IHC staining was performed using the Vectastain ABC kit (Vector, Burlingame, CA) 
per manufacturer’s instructions. Select p53 IHC was performed by the Histology/IHC Service at 
the University of Michigan.  
 
RNA Isolation and RT-PCR 
Tumors were sectioned and regions of tumor with human vasculature were confirmed via 
IHC. Serial sections of were dissolved in Trizol (Invitrogen, Carlsbad, CA) and RNA was 
extracted (PureLink RNA Mini Kit, Invitrogen, Carlsbad, CA) per manufacturer 
recommendations. RNA integrity was confirmed on the Agilent 2100 BioAnalyzer. PCR was 
performed for 40 cycles with primers at 100 nM concentrations (Supplementary Table 2). All 







Quantification of Vessels 
Vascular density quantification was performed as previously described (124). Five 
sections from each of three tumors in each tumor group were evaluated. Total mCD31 and 
hCD31 stain, as defined by pixel density and hue, was assessed using Olympus Microsuite 
Biological Suite Software. The area of staining was then compared between mCD31 and hCD31 
using a two-sided student t-test. hCD31+ tumor microvascular density following anti-THY1-
toxin therapy were similarly assessed. hCD31-PE and Alexa 594 Goat anti-GFP were used to 
assess human vessels either from tumor endothelial cell origin (PE+ only) or from hESCT origin 
(PE+ and GFP+). Sections were photographed in toto, and then quantitated using Olympus 
software as above.  
 
Immunotoxin Development and Delivery 
Anti-THY1-saporin immunotoxin was developed as previously described (124). 2 µg of 
freshly conjugated anti-THY1 antibody and saporin toxin, or an equimolar concentration of 
strepavidin-saporin, or unlabeled anti-THY1 antibody was incubated with 5x104 mesenchymal 
stem cells (MSC) in triplicate. After three days of treatment, viability cell was assessed using 
Trypan Blue. To test the efficacy of anti-TVM therapeutics in vivo hESCT-HEY1 tumors were 
treated with no treatment (n=3), or 2 mg of rat IgG-saporin (n=3), or anti-THY1-saporin (n=4).  
Immunotoxin was delivered intravenously every other day for 3 doses. Tumor growth was 
tracked using biofluorescent imaging with the Xenogen IVIS 200 imaging system and 
LivingImage software provided by the Center of Molecular Imaging of the University of 
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Michigan. Mice were monitored the day before and after treatment.  This experiment was 


























Vessels in hESCT-Cancer Model Express TVMs in a Cancer Cell Dependent Manner 
We generated hESCT-ovarian cancers (HEY1) and hESCT-breast cancers (MCF7) as 
previously described (122) using DsRED labeled cancer cells.   Immunofluorescence 
demonstrated clear, non-DsRED, human CD31+ vessels consistent with prior reports of human 
ESC derived vessels (91-93, 125). Human vessels were predominantly found in a peri-tumoral 
location (Fig I1A), and less frequently within the tumor islets and teratoma tissue. RT-PCR was 
performed to determine if the ovarian or breast specific TVMs were expressed in (1) HEY1 
ovarian cancer cell culture, (2) HEY1 ovarian tumor xenografts, (3) in vivo hESCT, or (4) in 
vivo hESCT- HEY1 ovarian tumors. In parallel we assessed the expression of ovarian or breast 
cancer specific TVMs were expressed in (1) MCF7 ovarian cancer cell culture, (2) MCF7 breast 
cancer xenografts, (3) in vivo hESCT, or (4) in vivo hESCT-MCF7 breast tumors.  We evaluated 
the expression of TVMs that have been reported to be upregulated in numerous tumors, 
including tumor endothelial marker-7 (TEM7), Integrin ß3, and THY1, as well as for TVMs 
reported to be ovarian cancer specific including EGFL6, P2Y-like receptor (GPR105), and 
F2RL1, or breast cancer specific such as FAP, HOXB2, SFRP2, and SLITRTK6. Unfortunately 
all TVM mRNAs (and every gene we have tested to date) were expressed in both hESCT and the 
ovarian cancer and breast cancer hESCT-cancer model, thus RT-PCR suggested TVMs were 
expressed in the hESCT but was otherwise uninformative (Fig I1B).  
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We next performed immunohistochemistry (IHC) to localize TVM expression within the 
cell line xenografts, hESCT, hESCT-HEY1 ovarian tumors, and hESCT-MCF7 breast cancers. 
Within hESCT controls, TVM protein expression could be identified in various developmental 
tissues, but expression was generally not found in vascular structures (Fig I2).  In contrast, the 
expression of ovarian TVMs could be detected within peri-tumoral vessels within the hESCT-
HEY1 ovarian tumors (Fig I2). Some vessels were clearly filled with red blood cells, indicating a 
connection with the murine vasculature and perfusion (Fig I2 and data not shown). Serial 
sections stained with anti-hCD31 antibody confirmed these structures as human vessels (Sup. Fig 
1). Identical results were obtained in a hESCT-SKOV3 ovarian cancer model (data not shown). 
Similarly, the breast cancer specific TVMs FAP, SFRP2, SLITRK6, and SMPD3, were all 
expressed in the hESCT-MCF7 tumors (Fig I2).  No vascular expression of any of the TVMs 
was detected in flank tumor xenografts (Fig I2) or in a murine ovarian tumor model 
(Supplemental Fig 2), demonstrating the IHC is not detecting murine tumor vessels.  
It remained unclear if the distinctions in the tumor vascular expression profile observed 
for different tumors is related to different methodologies of TVM identification, or a true 
distinction in the pattern of expression related to the tumor specific microenvironment. We 
therefore also assessed the vascular expression of ‘breast’ TVMs in the hESCT-HEY1 ovarian 
cancer model and the expression of ‘ovarian’ TVMs within the hESCT-MCF7 breast cancer 
model.  Interestingly vascular expression of the ‘ovarian’ TVMs F2RL1, GPR105 and EGFL6 
was not detected in the hESCT-MCF7 breast cancer model (Fig I2). Similarly the ‘breast’ TVMs 
FAP and SFRP2 were not expressed in the vasculature of the hESCT-HEY1 ovarian tumors (Fig 
I2). Rare vascular expression of the ‘breast’ TVMs SLITRK6 and SMPD3 was detected in the 
hESCT-HEY1 ovarian tumor model (Fig I2). These findings suggest that some TVMs are 
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expressed in a cancer specific manner and therefore likely induced by tumor cells, while others 
are more promiscuous and may identify angiogenic vessels or vasculogenesis.  
 
Enhancing Human Vascular Density in the hESCT Cancer Model 
A primary goal of this study was to determine if this model could be used to test anti-
human TVM immunotherapeutics. However, initial studies demonstrated that only a minority of 
resultant vessels (~15%) were of human origin with the remainder being murine vessels (see 
below). In order to increase the utility of the model for testing anti-vascular therapeutics, we 
attempted to increase the percentage of human tumor vessels in the hESCT-cancer model. As 
fibroblasts in the ovarian tumor microenvironment can significantly promote angiogenesis (31), 
we co-injected hESC and irradiated mouse embryonic fibroblasts (MEFs) to create a hESCT in 
which to inject HEY1 ovarian cancer cells.  Alternatively hESCT+MEFs we co-injected with 
HEY1 ovarian cancer cells and 5,000 FACS isolated VE-Cadherin+ primary ovarian tumor 
endothelial cells. Human CD31 IHC demonstrated the greatest number of human vessels in 
tumors co-injected with MEFs and VE-Cadherin+ cells (Fig I3A). Interestingly, while there were 
regions of the tumor, which had overlapping and interconnected human and murine vessels (Fig 
I3B), most regions of the tumor were dominated by either human or murine vessels (data not 
shown). IHC analysis of these vessels confirmed the expression of TVMs (data not shown).  
Quantification of the vascular density of murine and human vessels using co-IF with human 
CD31 and murine CD31 revealed that while the hESCT-HEY1 ovarian cancer tumor model 
alone had ~15% human vessels, the addition of MEFs increased the percentage of human vessels 
to ~40% (p value of 0.01, Fig I3C). With the addition of VE-Cadherin+ tumor endothelial cells 
nearly 80% of the tumor vessels were human (p value <0.0001, Fig I3C). HEY1 cells co-injected 
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with 5000 VE-Cadherin+ cells in matrigel in the animals flank, demonstrated no human vessels 
(data not shown) demonstrating the profound human vascularity is unique to the hESCT model.  
In order to determine if the increase in human vessels in the presence of VE-Cadherin+ cells was 
due to increased angiogenesis from the hESCT cells or proliferation of the VE-Cadherin+ cells, 
we repeated the above experiment using GFP labeled H7 ESC (Fig I3D).  Evaluation of tumor 
vessels demonstrated that 60-80% of the human vessels were GFP(-) and thus derived from the 
ovarian cancer VE-Cadherin+ cells while the remaining 20-40% of human vessels were GFP+ 
and therefore derived from hESCT cells (Fig I3E). These data demonstrate that the addition of 
human tumor vascular cells to this model leads to a dramatic increase in human tumor 
vasculature such that the majority of vessels present in the tumor are human in origin.  
 
Testing an Anti-TVM Therapeutic in the hESCT-Ovarian Cancer Model 
In order to test the utility of this model for screening anti-human TVM 
immunotherapeutics, we developed an immunotoxin targeting the human TVM THY1. This 
antigen was chosen due to the availability of commercial antibodies that can recognize the THY1 
antigen in vivo. In order to create the immunotoxin, streptavidin-conjugated saporin toxin was 
coupled to a biotinylated anti-human THY1 antibody. The cytotoxicity of this immunotoxin was 
confirmed in vitro against THY1+ primary human mesenchymal stem cells (MSC); anti-THY1-
immunotoxin resulted in statistically significant MSC death relative to antibody alone or saporin 
toxin alone controls (Fig I4A). In order to test the efficacy of anti-TVM-immunotoxin in vivo, 
anti-THY1-saporin (n=7 total in two experiments) immunotoxin or control rat IgG-saporin (n=6 
total in two experiments) was delivered intravenously to mice bearing hESCT-HEY1 DsRed 
tumors. Tumor growth was tracked with biofluorescent imaging. While rat IgG-saporin treated 
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tumors demonstrated continued growth, THY1-Saporin treated hESCT-HEY1 ovarian tumors 
demonstrated delayed growth and significant reduction in central tumor viability (the region 
dependent on human vessels) (Fig I4B-C).  Following completion of therapy, growth resumed in 
peripheral tumor regions that were dependent on murine vessels continued to expand (Fig I4B 
and data not shown). Control hESCT alone and HEY1-DsRED flank tumors showed no response 
to either therapy (data not shown).   
To further analyze the impact of anti-THY1 therapy on the human vessels, we quantified 
human tumor microvascular density using anti-hCD31 IHC. There was a three-fold reduction in 
the number of human vessels in hESCT-HEY1 ovarian tumors treated with anti-THY1 saporin 
toxin compared with Rat IgG-saporin toxin treated controls (Fig I4D). These results confirm the 
utility of this model for testing human TVMs specific therapeutics in vivo.  
 
The hESCT Model Promotes the in vivo Growth of Primary Human Cancer Stem Cells 
Human ovarian CSC have been particularly challenging to grow in vivo. Engraftment 
rates of CSC directly isolated from human ovarian tumors are only 20-40% in traditional flank 
tumor models and 5,000 CSC typically require 6-12 months to create a tumor (29). We 
hypothesized that the human microenvironment of the hESCT model with a human tumor 
vascular niche could greatly enhance the growth of ovarian CSC.  Using ALDH as an ovarian 
CSC marker (29), we assessed the efficiency of primary human ovarian CSC engraftment in the 
hESCT tumor model. We injected FACS isolated ALDH+ primary human ovarian CSC (700-
10,000) from 6 ovarian cancer patient samples into either hESCT or subcutaneously. hESCT 
were allowed to grow until they reached ~2000 mm3 (4-12 weeks after tumor cell injection).  
Histochemical analysis of resected hESCT-ALDH+ CSC demonstrated regions consistent with 
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papillary serous tumor growth (Fig I5A and data not shown).  In order to confirm these areas 
represent ovarian tumor cells, we exploited the recent finding that TP53 is mutant in >95% of 
serous ovarian tumors (126). TP53 IHC clearly identified human TP53+ serous ovarian tumors in 
all hESCT injected with ALDH+ ovarian cancer cells (Fig I5A and C).  Strong TP53 stain was 
not identified in hESCT alone or from hESCT injected with ALDH+ cells from a benign 
fibroadenoma (data not shown). ALDH+ ovarian cancer cells injected subcutaneously in the 
flank showed no growth during this time period.  Finally we repeated this experiment, directly 
comparing the growth within hESCT of ALDH+ and ALDH- cells within from 3 patients. hESCT 
injected with ALDH+ CSC demonstrated much more rapid growth than hESCT injected with 
paired ALDH- cells, indicating likely CSC engraftment in hESCT (Fig I5B).  Once again, TP53 
IHC of resected hESCT-ALDH+ CSC tumors demonstrated stain in regions consistent with 
papillary serous tumor growth (Fig I5C). No TP53 stain was noted in any of the hESCT-ALDH- 
cell tumors, thus the ‘tumors’ that grow in the ALDH- hESCT represent benign teratoma growth. 
These data demonstrate that primary ovarian CSC engraft in the human hESCT 












These data demonstrate that the hESCT-cancer model expresses bona fide human tumor 
vessels. These vessels express not only the expected human vascular markers such as CD31 but 
also tumor type-specific tumor vascular markers (TVMs) such as EGFL6 and TEM7. A central 
rationale for the development of such model system is for the testing of novel vascular-targeted 
therapeutics. A major challenge for developing antibody-based therapies targeting tumor vessels 
has been the lack of an animal model with a human tumor microenvironment and human vessels; 
antibodies targeting human antigens cannot be tested in traditional animal tumor models unless 
the antibodies happen to cross-react between species. The model advanced here addresses this 
issue and thus allows screening of potential immunotherapeutics targeting human vascular 
antigens. Similarly, this model can also be used to test the in vivo binding activity of vascular-
targeted peptides (122, 127, 128). 
The generation of large numbers of human tumor vessels in this model required the 
addition of VE-Cadherin+ human tumor vascular cells. Interestingly, the addition of only 5,000 
vascular cells led to nearly 80% human tumor vessels, ~70% of which were not derived from 
hESC, suggesting that the human VE-Cadherin+ cells are proliferating within the hESCT. 
Importantly, the human vessels in this model persisted throughout the period of tumor growth (4-
12 weeks after cancer cell injection).  
The need to add freshly isolated human tumor vascular cells could limit the widespread 
utility of this model. However, a significant number of human vessels (~40%) could still be 
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generated in the absence of human tumor vascular cells with the addition of irradiated mouse 
embryonic fibroblasts. It is possible that the addition of other pro-angiogenic cells such 
mesenchymal stem cells (129) or tumor-associated myeloid cells (130) could further increase the 
percentage of human vessels. One limitation for therapeutic testing with this model, as with other 
murine tumor models of human vasculature, is that tumors are still ultimately dependent on the 
murine vasculature for blood flow. Therefore, even with the complete therapeutic elimination of 
the human tumor vessels, tumors regions supplied by the murine tumor vasculature will continue 
to grow.  
While we used our model to confirm anti-vascular therapeutics, it can also potentially be 
used to test vascular imaging agents specifically targeting human vessels. This model allows 
testing the sensitivity of these compounds to detect tumor vasculature of ‘early stage’ tumors. 
We believe that this murine model offers a means to investigate the basic biology of human 
TVMs in vivo. Specifically, the mechanism of tumor specific TVM induction could be 
addressed, due to the power to independently modulate the expression patterns of the hESC and 
the cancer cells themselves. This may be particularly relevant given that we observed differential 
induction of some tumor-specific TVMs by breast versus ovarian cancer cell lines. 
Finally, the above data demonstrate that this model permits direct engraftment of primary 
human CSC in a manner more efficient than subcutaneous injections. This expands upon and is 
consistent with previous reports demonstrating improved growth of primary ovarian cell lines 
within hESCT as compared to tumor flanks (92, 93). Our previous studies using flank models for 
the engraftment of ALDH+ ovarian CSC demonstrated engraftment rates of ~20%, and tumor 
growth required 6-12 months (29). Using the hESCT model, we found 100% engraftment from 
as few as 700 ALDH+ primary human CSC within 4-12 weeks of tumor cell injection within the 
	  
45	  
hESCT. This model therefore represents a new tool to enhance the efficiency of the study of 
primary human CSC. This model could potentially be further improved with the addition of 
cancer associated mesenchymal stem cells (131). These findings emphasize the importance of 
the interplay between the tumor and the surrounding microenvironment and will allow a 
dissection of the signals within the tumor microenvironment that support cancer stem cell 





















We have confirmed the expression of human TVMs in a murine tumor model with robust 
human tumor vasculature.  Importantly many of these TVMs appear to be tumor type specific, 
indicating a tumor niche dependent induction of these TVMs. This model is a useful tool to study 
therapeutics targeting human tumor vessels. In addition, this model with its unique human tumor 
microenvironment allowed 100% engraftment of primary human CSC. The hESCT system will 
allow deeper probing of the role of the microenvironment dependent induction of TVMs, their 
role in tumor biology, and interactions in the tumor vascular/cancer stem cell niche.    
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Figure I1. Validation of human vasculature in the hESCT-cancer model. (A) Co-IF 
demonstrating the presence of hCD31+ (green) vascular structures in a peritumoral location with 
DsRed cancer cells. (B) RT-PCR of TVMs expression in the indicated cancer cell line cultures, 





Figure I2. TVM expression in the vasculature is influenced by the cancer cells. IHC 
localization of ovarian cancer specific TVMs, breast cancer specific TVMs and non-tumor 
specific general TVMs in the indicated tumors.  While TVMs are expressed in various 
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developmental tissues of the hESCT, vascular expression of TVMs is primarily seen only in the 
presence of cancer cells in a tumor type specific manner. n= 4 animals/group in two experiments. 










Figure I3. Enhancing the number of human vessels in the hESCT-cancer model. (A) IHC of 
hCD31 in hESCT-HEY1, hESCT-HEY1-MEFs, hESCT-HEY1+MEFs+VE-Cadherin+. (B) IF 
showing inter-connection of mouse and human vessels. (C) Quantification of mouse and human 
vessels in the hESCT-cancer model alone, with MEFs, or with MEFS and VE-Cadherin+ cells.  p 
values are indicated with error bars representing standard deviations.  n=4 animal/group.  (D) 
Co-IF demonstrating hCD31 stain (red) in both hESCT-GFP cells (green) resulting in yellow 
hESC derived vessels, and non-GFP cells originating from VE-Cadherin isolated patient tumor 
endothelial cells (patient vessels). (E) Quantification of the percentage of hESCT derived and 







Figure I4. Testing Anti-TVM Therapeutics in the hESCT-HEY1 ovarian tumor model. (A) 
Quantification of cellular death of THY1 expressing MSC treated with anti-THY1-saporin 
immunotoxin and controls. (B) Biofluorescence of hESCT-HEY1 DsRed ovarian tumor before 
and after two treatments with anti-THY1-saporin immunotoxin arrows indicated time of 
treatment. (C) Biofluorescent images of hESCT-HEY1 DsRED tumors before and after 
treatment with the indicated immunotoxins. (D) IHC images (1) and (2) quantification of human 








Figure I5. Growth of primary ovarian CSCs using the hESCT model. (A) TP53 IHC 
demonstrating ovarian cancer cells initiated by ALDH+ CSC injected within the hESCT. hESCT 
alone and ALDH+ cells from a patient with a benign fibroadenoma demonstrated no growth. (B) 
hESCT-ovarian tumor volumes from hESCT injected with 10,000 ALDH+ or ALDH- ovarian 
cancer cells from three patients.  (C) TP53 IHC of hESCT injected with ALDH- cancer cells and 
ALDH+ cancer cells demonstrating TP53+ papillary serous tumor growth from ALDH+ tumor 











Table 3. List of Antibodies Used 
 
 
Table 4. PCR Primers Used 
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ABSTRACT 
 A better understanding of ovarian CSC could lead to novel therapeutic. Unfortunately, 
the study of human CSC is hampered by heterogeneity of patients’ tumor samples, long 
requirements for tumor growth in vivo, and the need for tumor growth in immune-deficient mice.  
We have therefore characterized CSC in a transgenic murine model of ovarian cancer. This 
mouse model with conditional deletion of APC, PTEN and TP53 tumor suppressor genes 
develop advanced ovarian cancer similar to that seen patients. Cell lines derived from this tumor 
express numerous putative CSC surface markers including CD24, CD44, CD90, CD117, CD133 
and ALDH. CD24+ and CD133+ cells demonstrate increased tumor sphere forming capacity. 
CD133+ cells demonstrated a trend for increased tumor initiation in vivo while CD24+ cells vs 
	  
61	  
CD24- cells, had significantly greater tumor initiation and tumor growth capacity. No preferential 
tumor initiating or growth capacity was observed for CD44+, CD90+, CD117+, or ALDH+ versus 
their negative counterparts.  Consistent with a stem cell phenotype we have found that CD24+ 
cells, compared to CD24- cells, have increased expression of Nanog and c-myc and increased 
phosphorylation of STAT3.  JAK2 inhibition eliminated STAT3 phosphorylation and 
preferential targeted CD24+ cells. In vivo therapy with the JAK2 inhibitor TG101209 appeared 
to decrease tumor metastasis, and combined with chemotherapy, prolonged overall survival. 
These findings suggest that CD24+ cells have a CSC phenotype and may play a role in tumor 














Ovarian cancer is the fifth leading cause of cancer-related death among women (132). Most 
ovarian cancer patients present with advanced stage disease such that treatment with surgery and 
chemotherapy results in a median progression-free survival of only 16-22 months and a 5-year 
survival rate of only 27% (3). There are four major histologic subtypes of epithelial ovarian 
cancer: serous, endometrioid, clear cell and mucinous (4). The different subtypes are 
characterized by distinct genetic alterations (6). A better understanding of the specific pathway 
defects in the different ovarian cancer types will lead us to improve standard chemotherapies by 
including molecular targeted therapies specific to each cancer type (101).  
The clinical course of ovarian cancer, good initial response rates followed by high rates for 
relapse and the development of chemotherapy resistant disease, is consistent with the cancer 
stem cell model (115). Cancer stem-like cells (CSC) are a rare chemotherapy resistant cells 
within a tumor which can serve to repopulate the bulk of a tumor with more differentiated 
daughter cells and potentially contribute to recurrent disease (58). Several markers have been 
proposed as potential cancer stem cell markers in ovarian cancer including CD133, aldehyde 
dehydrogenase (ALDH), CD44, CD117 and CD24 (22, 54) (29, 64) (31) (24, 26, 115).   
The study of human CSC is very challenging due to patient samples variability, need of 
immunosuppressive mice and a long-term growth requirement for in vivo studies. The study of 
CSC in a murine tumor model provides a more homogenous means to study CSC with well-
defined genetic mutations in an immunocompetent microenvironment. There are currently 
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several genetic murine models of ovarian cancer, which utilize ovarian bursal injection of an 
adenovirus expressing cre recombinase (AdCre) to induce the deletion of specific ‘Floxed’ 
genes. Wu et al. developed a model of a high-grade endometrioid ovarian carcinoma, which 
develops after inactivation of APC, PTEN and TP53. This tumor model has 100% death due to 
widely metastatic disease similar to that of patients with advanced stage ovarian cancer patients 
(13).  
In this study we characterized cell lines and primary tumors from the Apcflox/flox; 
Ptenflox/flox ; Tp53 flox/flox ovarian tumor model for cells with ovarian CSC activity.   We 
demonstrate that cells with expression of the cell surface marker CD24 have greater sphere 
formation capacity, ability to passage, and ability to initiate tumors in vivo. We report that 
similar to that observed for hepatocellular carcinoma, CD24+ CSC demonstrate preferential 
expression of Nanog and phosphorylation of STAT3.  CD24+ cells are preferentially sensitive to 
inhibition of STAT3 phosphorylation with a JAK2 inhibitor.  Finally, we show that JAK2 
therapy in vivo using this tumor model seems to decrease tumor metastasis.  This studies 
supports other work demonstrating CD24+ cells as a metastatic CSC population and suggests that 
targeting JAK2 could reduce ovarian tumor metastasis.  
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MATERIALS AND METHODS 
Cell Culture 
Murine ovarian endometrioid adenocarcinoma cell lines were derived as previously 
described (133). Briefly, W2476T tumor cell line was established by mechanically dispersing 
ovarian tumor tissues with sterile scalpels followed by digestion at 37º C with 0.05% Trypsin-
EDTA for 20 minutes. Cells were cultured for five passages in DMEM containing 10% FBS and 
1% penicillin/streptomycin (p/s) in an incubator with 3% O2; 5%CO2. During the first five 
passages of primary culture, no adherent cells were discarded, and only adherent cells were 
passaged. W2476T cell line display epithelial (cobblestone) morphology. Cells were maintained 
and grown in RPMI containing 10% of FBS and 1% of p/s (Gibco, Grand Island, NY) at 37º C 
and 5%CO2.  
 
Isolation of Cancer Stem Cells from W2476T cell line and primary Apcflox/flox; Ptenflox/flox ; 
Tp53 flox/flox ovarian tumors 
Primary tumors were mechanically dissected into single-cell suspensions as previously 
described (29). Cells were isolated using fluorescence activated cell sorting (FACS). Briefly, 
primary ovarian tumor or cell lines single cell suspensions were counted and incubated with 
primary antibodies (CD24-PerCP Cy5.5, CD117-APC and CD133-PE from eBioscience San 
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Diego, CA) CD44-Pacific Blue (Biolegend, San Diego, CA), CD90-PE BD Pharmigen (San 
Jose, CA) for 30 min at 4º C. For ALDH+ sample, ALDH enzymatic activity was defined using 
the ALDEFLUOR kit (Stem Cell Technologies, Canada) as previously described (29). FACS 
was performed with ~ 1 x106 cells using FACSAria (Becton Dickinson, Franklin Lakes, NJ) 
under low pressure in the absence of UV light when possible.  
 
Sphere Assays 
Sphere culture was performed as previously described (29, 131, 134). Briefly, FACS-
isolated CD24+/-, CD44, CD90, CD117, CD133 and ALDH cell populations were plated in 
triplicates in either 6-well or 24-well ultra-low attachment plates in serum-free DMEM/F12, 
epidermal growth factor (EGF) 20ng/mL, gentamycin 20µg/mL, insulin 5µg/mL, 1% p/s (Gibco, 
Grand Island, NY), hydrocortisone 1ng/mL, ß-Mercaptoethanol 100µM (Sigma, St. Lois, MO), 
fibroblast growth factor (bFGF) (Millipore, Billerica, MA) 10ng/mL. Either 300 or 2000 cells 
were seeded in ultralow attachment plates (Sigma, St. Louis, MO) depending on the availability 
of cells to perform the experiment triplicates. Primary spheres were counted on day 5 and then 
dissociated enzymatically with 0.025% Trypsin-EDTA (Gibco, Grand Island, NY) for 2 minutes 
at 37º C and mechanically with Pasteur pipette. The cells obtained from dissociation were 
analyzed microscopically for single cellularity and then replated sphere formation assays. 





In vivo Tumor Models 
Mice were housed and maintained in the University of Michigan Unit for Laboratory 
Animal Medicine and all studies were performed with the approval of the University Committee 
on the Use and Care of Animals. ~5x104 W2476T-Luc FACS sorted cells for each cancer stem 
cell marker were injected subcutaneously into the axilla of CIEA NOG mice (Taconic, 
Germantown, NY) with 100ul of PBS and 200ul of matrigel (BD Biosciences, San Diego, CA). 
Two weeks after injection tumor growth was monitored weekly using in vivo bioluminescence 
imaging and tumor monitoring using caliper. For primary murine ovarian cancer cells, 
Apcflox/flox; Ptenflox/flox ; Tp53 flox/flox tumors were harvested and cells were dissociated and sorted 
for CD24+, CD24-  as stated above. 5x104 CD24+ and CD24- cells were injected into the 
contralateral flanks of NOG-SCID mice.  Tumor growth was monitored by injecting D-Luciferin 
(Biosynth)/PBS solution to each mice as previously described (131). Mice were imaged using an 
IVIS Image System 200 Series (Xenogen Corporation). Image acquisition was initiated 
approximately 10 min after injection of D-luciferin. The bioluminescence signals (photons/s) 
emitted from the mice were collected using sequential mode until reaching peak values and 
analyzed by LivingImage 3.0 sofware (Xenogen Corporation). Tumors were harvested before 
reaching 2000 mm3 and were measured for tumor volume, weighted and snap frozen for 
histologic analysis, RNA and protein. Tumor volumes were calculated using the L x W x W/2 
formula.  
Apcflox/flox; Ptenflox/flox ; Tp53 flox/flox tumor bearing mice were generated via intra-bursal 
AdCre injection as previously described (13, 101). TG101209 was reconstituted in dimethyl 
sulfoxide (DMSO) at 10mM and stored at -20º C and further diluted in 40µl of DMSO before 
injection. TG101209 was injected i.p. at concentrations of 50mg/Kg in a final volume of 40µL 
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daily for 3 weeks. Control mice were treated with 40µL of DMSO alone. 21 days of TG101209 
single agent therapy (50mg/kg n=5) or vehicle (n=5) was initiated 7 days after AdCre injection. 
For combined therapy with cisplatin, following AdCre injection mice were monitored until 
ovarian tumors were palpable (~4weeks).  Mice were paired by tumor sized and then randomized 
to treatment with cisplatin alone (once a week 2mg/Kg x 2 weeks and vehicle daily) or cisplatin 
+ daily TG101209 (n=6/group).  Mice were monitored in conjunction with the University of 
Laboratory and Animal Management and euthanized when (i) animal appeared ill with signs of 
weight loss, (ii) significant bowel distention, (iii) or primary ovarian tumors were felt to be 
~1000mm3. 
 
RNA Isolation and qRT-PCR 
W2476T cells were FACS isolated and RNA was extracted using PureLink RNA Mini 
kit, Ambion, Grand Island, NY) per manufacturer recommendations. RNA integrity was 
confirmed on the Agilent 2100 BioAnalyzer. Quantitative real-time PCR was performed for 40 
cycles using SYBR green (Applied Biosystems, Carlsbad, CA) as recommended by the 
manufacturer, with primers at 100nM concentrations. Expression was normalized to Transferrin. 
All transcripts were confirmed using 3% agarose gel electrophoresis.   
 
Western 
To detect a differential expression of pSTAT3 in CD24+ versus CD24- cells, ~3x105 
W2476T cells and CD24+/-  sorted cells were incubated overnight at 37ºC and 5% CO2. Protein 
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lysates were obtained after 1 hr incubation with TG10209. Protein concentrations were 
determined using the Bradford Protein Assay (Bio-Rad) using Spectra max (Molecular Devices, 
Downingtown, PA) and SofMaxPro V5 sofware. 20µg of protein lysates were separated on 4-
12% NuPAGE SDS gel (Invitrogen, Grand Island, NY) and detected using total STAT3 and 
pSTAT3 (1:1000 dilution, Cell Signaling Technology, Danvers, MA). Bands were visualized 
using the ECL Kit Pierce (Thermo Scientific, Waltham, MA). 
 
In vivo Cytotoxicity Studies 
MTT assays were performed as previously described (135). Briefly 5x103 W2476T cells 
were plated in each of a 96 well plate overnight and treated with increasing concentrations of 
Stattic (Sigma, St.Louis, MO) and TG101209 (gift from Talpaz Laboratory from University of 
Michigan). 24, 48 and 72 hours after plating medium was replaced with PBS + 2% FBS and 10µl 
of 12mM MTT from Vybrant MTT Proliferation Assay kit (Molecular Probes, Grand Island, 
NY) and incubated for 4 hrs. After a second incubation with DMSO for 10min at 37º C 
absorbance was read at 540nm using Spectra max (Molecular Devices, Downingtown, PA) and 
SofMaxPro V5 sofware.  Cell Adherent culture: 5x105 W2476T cells were seeded and treated 
with increasing concentrations of cisplatin (0, 0.1, 0.3, 1 and 3 µg/mL) daily for three 
consecutive days. TG101209 cells (0, 0.3, 0.6, 1 and 1.3µM) were administered on day 1 only.  
Cell number as a percentage of untreated control was assessed after 72 hours. Cells in 
suspension: For drug treatment in spheres, W2476T cells were first sorted for CD24 positive 
and negative populations then subjected them for sphere assay. 24hrs later, cells were treated 
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with Stattic or TG101209 for three consecutive days and then sphere were counted and subjected 




















In order to identify putative CSC in the Apcflox/flox; Ptenflox/flox ; Tp53 flox/flox ovarian cancer 
tumor model, we first used flow cytometry to analyze the expression of commonly reported CSC 
markers in the Apcflox/flox; Ptenflox/flox ; Tp53 flox/flox primary tumor derived W2476T tumor cell 
line  (Fig.II1A and B). We detected clear expression of CD24 (20-30%), CD44 (22-35%), CD90 
(1-2%), and limited expression of ALDH, CD117, and CD133 (0.5-1% each).  
As stem cells are characterized by the ability to grow in suspension and form spheres 
without the need of serum, we next tested the ability of FACS isolated cells expressing the 
specific CSC markers above to generate tumor spheres.  CD24+ and CD133+ cells generated 
more primary tumor spheres, and demonstrated a greater ability to passage to form secondary 
spheres (Fig. II2). 
 
CD24 Identifies Cells with Tumor Initiating Capacity 
 In vivo tumor initiation remains the gold standard for the identification of CSC.  We 
therefore next sorted luciferase labeled W2476T cells for each marker positive and their negative 
counterpart. Specifically, CD24+ Vs CD24-, CD44+ Vs CD44-, CD90+ Vs CD90-, CD117+ Vs 
CD117- and ALDH+ Vs ALDH-. We then injected 5,000 cells of each population subcutaneously 
in the axilla of NOG/SCID mice (n=5) and monitored tumor formation by bioluminescence. 
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Only CD24+ Vs CD24- cells had a statistically significant increase in tumor growth rates.  
CD133+ Vs CD133- cells demonstrated a trend for increased tumor growth. (Fig.II3 A-C). CD44, 
CD90, CD117, and ALDH demonstrated no significantly different tumor growth capacity 
between both marker positive and marker negative populations (See Supp Fig 3). Notice that in 
Fig II3A there is tumor formation by CD24- cells but it was not showed by bioluminescence. 
This is one of the limitations of the luciferase model for monitoring tumors. Importantly we 
performed weekly tumor monitoring measurement with caliper and when mice reached 
euthanization guidelines all tumors were measured and weighted.  
Given the improved tumor initiation capacity of CD24+ cells, we next performed tumor 
initiation studies with 200 CD24+ versus CD24- cells.   Consistent with a CSC phenotype, 200 
CD24+ cells Vs CD24- cells had a greater rate of tumor initiation (Fig. II4A-C). In addition, 
CD24+ cells were capable of serial passage through at least three generations (data not shown). 
50,000 CD24+ cells of primary Apcflox/flox; Ptenflox/flox ; Tp53 flox/flox tumors formed 5/5 tumors 
whereas CD24- cells formed 2/5 tumors (data not shown). 
 
CD24 Cells Preferentially Express Stem Cell Genes and Phosphorylate STAT3 
Given greater tumor sphere formation capacity, passaging potential, and greater tumor 
initiation rates in vivo we next characterized stem cell gene expression in CD24+ and CD24- 
population (Fig II5A). W2476T whole cell line, and sorted cells CD44+ and CD44- were used as 
controls (Supplemental Fig 4). While no differential expression was noted in controls qRT-PCR 
analysis demonstrated CD24+ Vs CD24- cells had increased expression of Nanog, c-myc and 
Cyclin D1.  
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Interestingly, CD24 has been reported as a CSC marker in hepatic cancer.  CD24+ cells in 
hepatic cancer similarly had increased expression of Nanog, and it was found that Nanog 
promoted cellular self-renewal via phosphorylation of STAT3. We therefore next evaluated 
pSTAT3 in CD24+ and CD24- cells. Whole cell line W2476T chemosensitization was performed 
(Fig II5 B). CD24+ cells showed increased basal levels of STAT3 phosporylation compared to 
the CD24- cells (Fig II5C). We next treated whole W2476T, or FACS isolated CD24+ and CD24- 
cells with the direct STAT3 inhibitor Stattic, or the JAK2 inhibitor TG101209 which indirectly 
inhibits STAT3 phosphorylation.  Surprisingly, TG101209 inhibited pSTAT3 more efficiently in 
isolated CD24+ cells than Stattic (Fig II5C).  In order to determine the functional importance of 
STAT3 phosphorylation, we treated CD24+ and CD24- spheres with both Stattic and TG101209. 
Both Stattic and TG101209 preferentially decreased CD24+ primary sphere growth, and 
essentially eliminated passaging potential, suggesting an important functional role of STAT3 in 
CD24+ ovarian tumor cells (Fig II5 D-E).  
In order to confirm anti-tumor activity of inhibiting STAT3 phosphorylation via JAK2 
inhibition in vivo we assessed the impact of JAK2 inhibition on Apcflox/flox; Ptenflox/flox ; Tp53 
flox/flox ovarian established tumors.  Tumors were established and monitored until tumors reached 
~500mm3.  Tumors were paired based on size and then randomized to cisplatin Vs. cisplatin + 
TG101209 for 21 days. Combinatory treatment of cisplatin plus TG101209 improved survival of 
mice compared with mice treated with cisplatin only (Fig II6A-B).   
  We next treated  ‘early onset’ ovarian cancer mice with TG101209. TG101209 or control 
therapy was initiated one week after injection of AdCre (Fig II7A). Unexpectedly, while control 
mice had tumor nodules in the intestine, liver and peritoneum, mice treated with TG101209 had 
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little or no tumor nodules (Fig II7B-D). This study will be repeated with a higher number of mice 




















Genetic models of cancer represent a homogenous and reproducible means to study CSC.  
Murine models also offer the advantage of an immunocompetent host.  We found that in the 
Apcflox/flox; Ptenflox/flox ; Tp53 flox/flox murine tumor model that CD24+ cells that contain a subset of 
cells with increased tumor sphere forming and tumor-initiating capacity.  CD24+ cells 
preferentially express the stem cell genes Nanog, cyclin-D1, and c-myc and have increased 
pSTAT3 levels.  Interestingly, Nanog (42, 136), Cyclin D1 and c-myc (137, 138) have been 
previously reported to be regulated by STAT3. 
In this study we found that CD24+ cells have increased basal pSTAT3 and that in vitro 
blockade of pSTAT3 was associated with decreased proliferation. Blockade of STAT3 
phosphorylation in vivo was associated with near complete loss of metastasis, implicating CD24+ 
cells in metastasis.  This is supported by numerous other reports,  Gao and colleagues reported 
that CD24+ primary human ovarian cancer in addition to having the stem cell characteristics of 
quiescence, chemoresistance, and tumor initiation (26) also exhibited a epithelial-mesenchymal-
transition (EMT) (133) phenotype, with high invasive capacity.  Suggesting a direct role for 
CD24 in EMT, shRNA depletion of CD24 suppressed cell invasion and reversed the EMT 
phenotype (139). While there is increasing evidence of the role of CD24 in metastasis, the exact 
mechanism remains uncertain.  CD24 may act both as an adhesion molecule to promote cellular 
migration.  CD24 can bind to P-selectin and directly support the rolling of breast carcinoma cells 
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on endothelial cells. Similarly CD24 has been reported to directly support the adhesion, 
migration and invasion in colon and pancreatic cell lines (140).   
CD24 also appears to play an important role in signal-transduction to promote metastasis. 
CD24 is reported to physically interact with c-src in both breast and ovarian cancer to regulate 
STAT3 (141-143).  In hepatocellular carcinoma, CD24 has been shown to promote self-renewal 
through Nanog mediated by STAT3 phosphorylation (42).  Our studies suggest that the 
activation of STAT3 plays a critical role in CD24+ cell metastasis. STAT3 phosphorylation can 
be mediated by either Src or JAK2 (42, 143). Unlike previous studies, which implicated Src in 
CD24 mediated STAT3 phosphorylation, our studies indicate a critical role for JAK2.   
For our in vitro studies we used both Stattic, direct pSTAT3 inhibitor and TG101209 a 
JAK2 inhibitor that prevent STAT3 phosphorylation. Interestingly, while both Stattic and 
TG101209 block STAT3 phosphorylation in isolated CD24+ cells, TG101209 effectively 
blocked STAT3 phosphorylation more efficiently. We observed no change in p-Src (Y416) in the 
W2476T cell line, CD24+ and CD24- treated with Stattic or TG101209, suggesting that in this 
particular cell line, phosphorylation of STAT3 goes through JAK2 and not Src. It is important to 
note that TG101209, in addition to inhibition JAK2, also inhibits FLT3, RET kinases (144).  
Further studies will be necessary to determine if inhibition of either FLT3 or RET is contributing 
to the metastasis inhibiting role of TG101209.  Furthermore, in our in vivo studies we cannot 
rule out an important contribution of TG101209 activity on the tumor microenvironment 
contributing to inhibition of metastasis.    
Ovarian cancer has been classified in type I and type II. Endometrioid, clear cell, 
muscinous and low grade serous carcinomas are classified as type I ovarian cancer (11, 13). In 
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contrast, type II ovarian cancers are high grade, biologically aggressive tumors from the 
beginning, with a tendency for metastasis from small-volume primary lesions (11, 13). High-
grade serous ovarian carcinomas are type II ovarian carcinomas, which possess TP53 mutations 
(9, 10). Interestingly, type I and type II ovarian cancer have overlapping features suggesting that 
a subset of epithelial ovarian cancer may undergo type I to type II progression along with the 
acquisition of somatic TP53 mutations (13). The Apcflox/flox; Ptenflox/flox ; Tp53 flox/flox mouse 
model of ovarian cancer used in this study carry the genetic mutations APC/PTEN commonly 
observed in type I tumors, however, with the addition of the TP53 mutation assuming a much 
more aggressive/metastatic phenotype consistent with progression from type I to type II.  
Interestingly, with the administration of TG101209 there appears to be a pharmacologic 
reversion of these aggressive tumors back to a type I phenotype with disease essentially confined 
to the ovary. 
Our data would indicate a potentially important role for JAK2 inhibitors in patients with 
ovarian cancer; the ability to prevent metastasis could dramatically improve the outcomes of 
patients with ovarian cancer and prevent complications such as bowel obstruction. However, as 
JAK2 inhibition did not affect the growth of primary tumors, novel endpoints for trial design will 
need to be consider as resist criteria alone may discount an important therapeutic benefit. 
One clinical setting in which JAK2 inhibition could be very potent in ovarian cancer is as a 
chemoprophylaxis.  JAK2 inhibitors are oral, relatively well tolerated medications. The use of 
JAK2 inhibitors in women at high risk for ovarian cancer to prevent metastatic spread prior to 





In conclusion, we show that CD24 is a putative CSC marker of the Apcflox/flox; Ptenflox/flox; Tp53 
flox/flox mouse model of ovarian cancer. This model will be a useful means to study ovarian CSC 
in an immunocompetent host. Using this model we have found that JAK2 inhibition improves 









Figure II1. Analysis of stem cell marker expression in cell lines and primary tumors 
derived from the Apcflox/flox; Ptenflox/flox ; Tp53 flox/flox ovarian mouse model. (A) FACS plots of 
the indicated markers and isotype controls of W2476T cell line (B) Summary of average 
percentage of CSC marker expressing cells (C) Summary of average percentage of CSC marker 




Figure II2. Functional Asssessment of CSC activity. Summary of average numbers of primary 
and secondary tumors spheres formed 300 FACs isolated cells expressing the indicated CSC 























 Primary Spheres Day 5 




Figure II3.  CD24+ demonstrate preferential tumor initiation capacity. (A) Bioluminescent 
images of W2476T-Luc tumors formed from cells, which express or do not express the indicated 
CSC marker.  (Right axilla CSC marker positive cells and left axilla CSC marker negative cells) 
(B) Tumor weight of tumors generated from different stem cell markers (C) Tumor volume of 
CD24 +/- and CD133+/- tum 
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Figure II4. W2476T-Luc Dilution experiment for CD24 stem cell marker. (A) Luminescence 




















































Figure II5. CD24+ cells preferentially expresses stem cell genes and have increased levels of 
pSTAT3. (A) qRT-PCR Comparison of stem cell gene expression in W2476T whole cell line 
and sorted CD24+ and CD24- cells.  (B) Chemosensitization assay of W2476T cells with 
TG101209 (C) Western blot showing differential phosphorylation of STAT3 in CD24+ and 
CD24- cells and inhibition by Stattic and TG101209 (D) Primary and secondary (E) spheres 
treated with Stattic and TG101209 for three consecutive days and counted on day 5. Showing 











































































































































































































































Figure II6. Combination of cisplatin and TG101209 treatment in Apcflox/flox; Ptenflox/flox ; 
Tp53 flox/flox mice improves survival. (A) Timeline of cisplatin and TG101209 treatment (B) 











Figure II7. Treatment of Apcflox/flox; Ptenflox/flox ; Tp53 flox/flox mice with TG101209 restricts 
metastasis. (A) Timeline of TG101209 treatment (B) Mice treated with TG101209 and contro 
(DMSO). Arrows indicate metastasis and primary tumor (C) Total metastasis volume p< 0.001 
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We have described two models to study ovarian CSC. Previously human ovarian CSC 
studies have been hampered by the low engraftment rate in xenografts using immunosuppressed 
mice. Therefore we developed a model system in which human embryonic stem cells offer a 
human microenvironment by forming a teratoma in the mouse. We improved this model by 
adding tumor endothelial cells to enrich the percentage of human tumor vessels and therefore 
provide an enhanced microenvironment/CSC niche for human ovarian CSC growth. This model 
system offers a new tool to study human ovarian CSC growth and test therapeutics specifically 
targeting human tumor vessels.  
While the hESC model overcomes poor engraftment rates associated with in vivo human 
ovarian CSC growth, in vivo study human ovarian CSC remains challenging due to significant 
patient heterogeneity, the need to use of an immunosuppressive microenvironment, and a long 
latency before tumor formation. Therefore we studied a second model for ovarian cancer. We 
characterized ovarian CSC in a mouse model of ovarian cancer with genetic mutations in APC 
PTEN and TP53 that resembles type II ovarian cancer. The advantages of this model are: it is 
homogeneous, it has defined genetic defects reflecting human disease, tumors develop rapidly, 
and it offers an immunocompetent microenvironment. From this mouse model of ovarian cancer 
we found that CD24+ cells have characteristics of CSC including sphere formation in vitro and 
increased tumor initiation and growth in vivo. Studies have shown that CD24 promotes self-
renewal through Nanog mediated activation of STAT3. CD24+ cells were demonstrated 
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preferential activation of STAT3. In vivo treatment with TG101209, which is an indirect 
inhibitor of STAT3 phosphorylation, significantly decreased metastasis associated with this 
aggressive ovarian cancer model.  Finally, when TG101209 was combined with chemotherapy, 
we observed prolonged overall survival. These findings indicate that CD24 population have a 
CSC phenotype and may play a role in tumor migration and invasion in other organs. Moreover, 
these findings suggest that combination of chemotherapy and CSC targeted therapies can 
potentially improve survival by inhibiting metastasis.  
 
Tumor Vascular Markers, the Extracellular Matrix and the CSC niche 
Tumor vasculature has a markedly different gene expression pattern than normal 
vasculature. Most of differentially expressed tumor vascular genes are involved in extracellular 
matrix formation or remodeling. For example, St. Croix et al. compared endothelium from colon 
cancer to normal endothelium and found that at least seven of the differentially expressed genes 
encoded proteins were involved in extracellular matrix formation and remodeling (3). Similarly, 
glioma endothelial cells study upregulate tumor endothelium extracellular matrix components 
such as heparan sulfate proteoglycan 2, type II collagen and matrix metalloprotease 14 (4).  In 
breast cancer endothelial cells, genes that regulated the extracellular matrix were found to be 
osteonectin and matrix metalloprotease 9, and tissue inhibitor of metalloproteinase 1 (5).  In 
ovarian cancer, tumor endothelial cells showed a differential expression on adlican (matrix 
remodeling associated 5, MXRA5); C11orf8 (metallophosphoesterase domain containing 2, 
MPPED2 and Collagen typeXI alpha-1 (Col11A1) (6).  
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The unique extracellular matrix created by tumor endothelial cells likely contributes to 
the CSC niche. Niches play a protective role by shielding stem cells from environmental insults 
as well as regulating stem cell proliferation and cell fate decisions (7). It has been suggested that 
the vascular niche protects CSC from chemotherapy and radiotherapy to promote tumor 
recurrence (7-9). Brain CSC have been shown to grow near the tumor vasculature (7) where the 
endothelial cells provide secreted factors that maintain these cells in a self-renewing and 
undifferentiated state. Furthermore, Calabrese et al. showed that antiangiogenic therapies which 
reduce tumor blood vessels arrested tumor growth with a restriction in CSC number (7). These 
findings suggest that the vascular niche represents a therapeutic target to impact CSC.  
 Given the role of the vascular cells, both in providing nutrients for cancer growth and in 
creating a niche for CSC, inhibiting or destroying tumor vessels using either anti-angiogenic 
agents or vascular disrupting agents is a very attractive treatment approach. However, given 
many human tumor vascular targets are not expressed on murine tumor vessels, most murine 
tumor models are insufficient for anti-human tumor vascular targeted therapy studies.  Therefore 
our model system offers a microenvironment with human tumor vessels where we can test the 
efficacy of targeted therapies specifically to human tumor vessels. Similarly, this model can also 
be used to test the in vivo binding activity of vascular-targeted peptides (10).  We proved the 
power of this model using both human specific vascular targeting antibodies (1) and vascular 
targeted nanoparticles (11).  Future studies will be necessary to assess the impact of vascular 





Future Experiments with the hESCT Tumor Model 
This work lays an important foundation for numerous future studies.  The hESCT-tumor 
model can be further developed and ultimately individualized for a given patient with the goal of 
identifying therapeutic response.  We have previously identified other components of the human 
CSC niche including tumor associated macrophages and mesenchymal stem cells.  The hESCT 
model system could be expanded to include addition of these cellular components directly 
derived from a patient's primary debulking sample. With the addition of tumor endothelial cells, 
mesenchymal stem cells, tumor associated macrophages, and cancer stem cells a human tumor 
could be nearly completely reconstructed within the mouse. Such a system could then be used to 
test therapeutics targeting either tumor vasculature, CSC or both. This will allow us to re-create 
the tumor in a more similar environment where it was and test therapeutics and find the most 
efficacious one and eventually if these drugs are approved then give to the patient.  
The sources to of human vessels in the mouse such human embryonic stem cells and 
human tumor endothelial cells to grow in the mouse have certain disadvantages. First of all 
human embryonic stem cells in vitro growth are time consuming and patient tumor endothelial 
cells are difficult to obtain and are very difficult to expand in vitro therefore need to be injected 
into mice as soon as possible. Another easier option to potentially grow human vessels in the 
mouse is the use of endothelial cell lines.  One very good candidate cell line is infantile 
hemangioma cell line. Infantile hemangioma is a vascular neoplasm resulting from abnormal 
proliferation of endothelial cells. Hemangioma stem cell lines have been developed and when 
injected into immunosuppresed mice recapitulate a hemangioma tumor with human vessels (12). 
It will be appealing to inject hemangioma cells, with ovarian tumor cells and evaluate if these 
express ovarian TVMs. Also, following the before mentioned approach we could inject these 
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along with mesenchymal stem cells and CSC and having an easier model system than the need of 
hESCT.  
While the hESCT model system has advantages, it is highly laborious, uses 
immunosuppresed mice and there is patient to patient CSC variability. The transgenic mouse 
model of ovarian cancer represents an important additional model for more expeditious studies 
of ovarian CSC in parallel with the hESTC model since we know the genetic deficits, which 
resemble human disease, is homogeneous and represents an immunocompetent 
microenvironment.  
CD24, Cancer Stem cells and Epithelial Mesenchymal Transition 
Emerging data have highlighted shared molecular characteristics of CSC and EMT cells 
(13, 14). EMT is also believed to enhance metastasis due to the increased migratory capacity of 
mesenchymal cells. EMT has a central role in embryogenesis and is well recognized for its close 
connection to cancer metastasis also in ovarian cancer (15). In ovarian cancer, cells with a 
mesenchymal phenotype have been shown to be more resistant to chemotherapy than epithelial 
cells (16-18). It was previously shown by Kang et al. that CD24+ population of human ovarian 
cancer cell line and primary ovarian cancer clone exhibit an EMT phenotype, high invasive 
capacity, and CXCR4/SDF-1 mediated chemotactic migration (19). Furthermore, depletion of 
CD24 by shRNA suppressed cell invasion and resulted in a loss of an EMT phenotype (19). In 
our hands, preliminary data shows that W2476T CD24+ cells similarly have a mesenchymal 
phenotype with increased expression of mesenchymal genes compared to CD24- population (data 
not shown). We also found that these cells were more invasive in vitro (data not shown).  
Furthermore, treatment of tumor in vivo resulted in fewer metastases.  However, we cannot 
	  
94	  
definitively determine if this is secondary to CD24+ cell specific toxicity. In order to assess if the 
loss of metastases is specifically due to toxicity of CD24+ cells, CD24+ and CD24- cells could be 
injected in the ovarian bursa orthotopically and test if there are metastatic differences among the 
two different populations.  
 
CD24, IL6/JAK/STAT pathway and Metastasis 
Our studies show that CD24 is a stem cell marker in this mouse model of ovarian cancer 
in which pSTAT3 may play a role in stem cell self renewal and in tumor metastasis. CD24 has 
been shown to promote self renewal through STAT3 mediated Nanog (20). Additionally, CD24 
is linked to tumor invasion (21) and metastatic progression (22, 23). It has been shown that 
CD24 on the surface of tumor cells can bind P-selectin on vascular endothelial cells and platelets 
to promote tumor metastasis (24, 25). Therefore, cancer cells with high CD24 expression might 
invade the vessel lumen and bind with platelets, resulting in vascular or lymphatic metastasis 
(24).  
It has been previously reported that IL-6 plays a role in progression of epithelial ovarian 
cancer (26, 27), suggesting IL-6/JAK/STAT pathway may play a role in ovarian cancer 
metastasis. Supporting a role for IL6 in metastasis, IL-6 augments the tumorigenic potential and 
invasiveness of EOC cells by inducing the secretion of metalloproteinase-9 (28). Moreover, in a 
3D co-culture of mesenchymal stem cells and ovarian cancer cells IL-6 promoted invasion and 
migration of ovarian cancer cells (29).  In breast cancer there is an autocrine/paracrine IL-
6/JAK/STAT3 feed-forward loop, which participates in tumor proliferation, shaping of the tumor 
microenvironment, and metastasis (30). Chang et al. examined the levels and distribution of IL-6 
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expression by immunohistochemistry in human primary breast cancers including those with 
metastatic involvement in matched axillary lymph nodes (30). They found that the highest levels 
of IL-6 were found in the tumor edge enriched in stromal/immune cells, areas of 
lymmphovascular invasion, and axillary lymph nodes (30). Moreover, they found a correlation 
between high levels of IL-6 on the tumor edge and the number of lymph nodes affected by 
metastatic disease.  
Normal stem cells are regulated by their microenvironment and CSC are regulated by 
cells in the tumor microenvironment. These interactions involve inflammatory cytokines, such as 
IL-1, Il-6 and Il-8 which in turn activate STAT3/NF-kB pathways in both stromal and tumor 
cells (31). Activation of these pathways stimulates further cytokine production, generating 
positive feedback loops that in turn drive CSC self renewal (31) . Interestingly, these pathways 
are normally activated during inflammation and wound healing and may contribute to the known 
link between inflammations and cancer. Inhibitors if these cytokines and their receptors have 
been developed as anti-inflammatory agents. By blocking signals from the tumor 
microenvironment these agents have the potential to target CSC. In our studies, we decreased 
metastasis by targeting JAK2 and consequently phosphorylation of STAT3. One may 
hypothesize that STAT3/NF-kB pathways are activated by ovulation induced 
inflammation/wound healing. If aberrant inclusion cysts are created, these may lead to chronic 
inflammation and ultimately initiate ovarian cancer. 
IL6 signaling is mediated by inflammation and IL6 receptor activation results in the 
phosphorylation of the receptor and JAK2, which recruits its substrate proteins such as signal 
transducers and activators of transcriptions (STATs). STATs, especially STAT3 and STAT5, 
translocate to the nucleus and transactivate many genes involved in cell proliferation and 
	  
96	  
survival (ex. Cyclin D1).  Like IL6, the JAK/STAT signaling is strongly linked with 
oncogenesis.  The JAK/STAT signaling pathway is frequently activated in leukemia and other 
hematological disorders. This may occur via activating mutations upstream cytokine receptors, 
including FLT3, c-kit and G-CSFR, and constitutively active JAK kinases, such as JAK2 V617F 
and TEL-JAK2. In addition, alterations of the downregulator of this pathway could also 
contribute to aberrant activation (32).  
Our findings contribute to a growing body of literature of the role of the JAK/STAT 
pathway in cancer. We found that the JAK2 inhibitor TG101209: [1] Decreases CD24+ sphere 
formation, [2] Inhibits phosphorylation of STAT3 in W2476T ovarian cancer cell line, [3] 
Blocks metastasis in vivo and [4] If combined with cisplatin improves survival in a mouse model 
of ovarian cancer.  
Consistent with our studies, Chang et al. found that the JAK2 inhibitor ruxolitininb 
inhibited tumor growth, metastatic nodules and reduction of phosphorylation of STAT3, 
infiltrating endothelial cells and fibroblast/myoepithelial cells (30).   
It is important to note that, while TG101209 is most active against JAK2 (IC50=6nM), it 
also inhibits FLT3, RET and JAK3 kinases with IC50 of 25-169 nM in vitro kinase assays (33). 
Thus, while we used TG101209 at low doses in vivo, we cannot rule out that some of the anti-
metastatic effect of TG101209 is secondary to effects on these other kinases. In addition, while 
we observed no significant changes in the number/types of host cells in the tumor 
microenvironment in the presence and absence of TG101209 treatment, it is also possible 





Recently, two independent studies show that if normal stem cells are depleted, 
differentiated cells of the stomach (34) and lung (35) can act as adult stem cells, generating 
various cell types of the tissues including a pool of stem cells. Further studies need to be done if 
this is also applicable in CSC. In our hands, W2476T CD24- cells formed less and smaller 
tumors than CD24+ population (See Fig II3 and II4). When we analyzed the tumor cells we 
observed that CD24- tumors primary tumor cells contained CD24+ and CD24- cells (data not 
shown). This could be due contamination from the FACS (meaning CD24- cell pool mistakenly 
harbored CD24+ cells) or that CD24- cells formed CD24+ cells. In the above recent studies, Tata 
et al. shows that in the trachea contact between differentiated Clara lung cells and lung basal 
stem cells inhibits dedifferentiation of Clara cells. Suggesting maybe CD24- cells 
dedifferentiated due to the absence of CD24+ cells and regenerated CD24+ and CD24- cells. 
However further studies need to be accomplished to understand why primary CD24- tumors 
generated CD24+ and CD24- cells.  
 
Applying these Findings in Other Ovarian Cancer Types 
It will be interesting to obtain endometrioid adenocarcinoma patient tumor samples and 
analyze if CD24 is a good candidate for CSC in that specific epithelial ovarian cancer type. 
Previously it has been shown by us (2) and others (36-40) that the most common stem cell 
marker candidates for serous ovarian cancer are ALDH and CD133. It will be worthy of note to 
test if CD24 is higher in the CSC hierarchy in endometrioid ovarian cancer type in comparison 
with ALDH and CD133.  
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Origin of ovarian cancer 
Epidemiologic studies have shown a significant reduction in risk of ovarian cancer 
directly related to increased parity and the use of contraceptive pills. This suggests an important 
factor in ovarian cancer is ovulation (41). One hypothesis on the origin of ovarian cancer is that 
normal fallopian tube epithelium from the fimbria implants at the site of rupture of OSE when 
ovulation occurs, leading to the development of a cortical inclusion cyst (CIC) that may undergo 
malignant transformation (42). There appear to be two types of ovarian CICs. One type results 
from invagination of OSE with a flattened epithelium. The second type is lined by ciliated 
columnar epithelium which is histological identical to the fallopian tube epithelium (42). 
Suggestive that CICs are derived from fallopian tube epithelium is the finding of leukocyte 
populations, including CD3+ T cells, CD8+ T lymphocytes and CD68R+ macrophages are 
present in CICs (42, 43); Fallopian tube epithelium contain these immune cell populations while 
OSE does not. These leukocyte populations may be involved in immune mucosal protection and 
through their role in inflammation, may contribute to neoplastic transformation (42). This may 
be due to the destruction and repair of OSE during ovulation, which is accompanied by 
inflammation that probably plays a role in ovarian cancer (44).  
If fallopian tube derived CICs are a putative source of ovarian cancer and CSC are also 
important for ovarian cancer initiation, then it would be anticipated that stem like cells would be 
present in the fallopian tube and CICs. Indeed, recently Auersperg showed that even though the 
fimbrial epithelial cells are highly differentiated, some cells express stem cell markers such as 
Nanog, ALDH1A1 and ALDH1A2 and these markers are also present in the human (45) and 
mouse (46) OSE. Importantly these markers were present in the distal parts of fimbrial 
epithelium, which are also the sites of serous tubal intraepithelial carcinomas (STICs), the 
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putative precursors of high grade serous ovarian cancer (45, 47). If the fimbrial epithelium 
expresses Nanog (45) and the ovarian surface inclusion cysts expresses Nanog and CD24 (45, 
48), then one may speculate that serous ovarian cancer may originate from altered Nanog 
expressing distal fimbria that has translocated into the OSE and then becoming entrapped within 
the ovarian stroma. This may happen during ovulation because the fimbria and the OSE are in 
closer contact during ovulation of inflammation (49). It will be interesting to determine whether 
the normal mouse ovaries have CICs expressing Nanog and CD24 and compared it to different 
time points after induction of ovarian cancer after injection of AdCre in the ovarian bursa 
inactivating APC, PTEN and TP53 genes. These findings will help us understand the recently 
published results were Schereiber at al. showed that CD24 and Nanog were in the cyst walls of 
81% of human serous ovarian carcinomas and the source of this disease. 
 
Future Directions for detecting CSC in Mouse Model of Ovarian Cancer 
In this study we show that mice bearing ovarian cancer with APC PTEN TP53 mutations 
have a decrease in metastasis when treated with TG101209. At this time we lack the information 
of how specifically the drug is preventing metastasis. In order to address this issue several 
studies need to be accomplished. First, it will be important to confirm TG101209 is acting on 
tumor cells primarily and not on the host cells. If treatment effects are primarily due to inhibition 
of JAK2 on the tumor cell then knockdown of JAK2, in the W2476T cell line and evaluate if this 
cells are able to migrate/invade and metastasize in vitro and in vivo. To further confirm that the 
impact is due to targeting JAK2 and not off target effects on JAK1 or FLT3, we could also use 
specific inhibitors of JAK1 or FLT3 and evaluate if these decrease metastatic nodules as well as 
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TG101209. Further evaluation of CD24 and metastasis is needed. Knocking out CD24 in 
W2476T cell line and evaluation of this in vitro and in vivo may give us some answers how 
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                                                                ABSTRACT 
 
Recent studies indicate that ovarian cancer may be highly responsive to anti-vascular 
therapeutics.  We have developed an anti-vascular tumor therapeutic using the F3 peptide to 
target cisplatin loaded nanoparticles (F3-Cis-Np) to tumor vessels.  We demonstrate that while 
F3-Cis-Np bind with high specificity to both human ovarian tumor cells and tumor endothelial 
cells in vitro, they only demonstrate cytotoxic activity against the tumor endothelial cells.  In 
vivo these nanoparticles bind primarily to tumor endothelial cells.  Therapeutic studies in both 
flank and orthotopic intraperitoneal murine ovarian tumor models, as well as human tumor 
xenograft models, demonstrate rapid tumor regression with treatment.  Treatment was associated 
with significant vascular necrosis consistent with an anti-vascular effect.  Furthermore treatment 
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was active in both platinum sensitive and platinum resistant cell lines. Importantly we 
demonstrate that F3-Cis-Np bind to human tumor endothelial cells in vitro and to human tumor 
vessels in vivo.  Therapy targeting human vasculature in vivo with F3-Cis-Np led to near 
complete loss of all human tumor vessels in a murine model of human tumor vasculature.  Our 
studies indicate that F3-targeted vascular therapeutics may be an effective treatment modality in 






















Ovarian cancer is a deadly disease for which there have been few new therapies. For the 
past decade platinum and taxane chemotherapy regimens remain the mainstay of therapy.  The 
development of targeted and biologic therapies for ovarian cancer has lagged behind other tumor 
types.   Recent studies have suggested angiogenic pathways are important therapeutic targets in 
ovarian cancer.  Phase II trials suggest a significant response rate of ovarian cancer to anti-VEGF 
therapy (174-177).  This is unlike other solid tumors such as colon, lung, and breast cancer 
which showed no response to single agent anti-VEGF therapy.  When anti-VEGF therapy is used 
in combination with chemotherapy in ovarian cancer, response rates are even higher (178, 179). 
Unfortunately, even when used in combination with chemotherapy, response to anti-VEGF 
therapy is relatively short.  This is due in part to host cell up-regulation of alternate angiogenic 
pathways (180).  
Targeting vascular cells directly represents a means to target numerous angiogenic 
pathways which act ultimately at the endothelial cell.  In addition, unlike traditional anti-
angiogenic therapies which prevent new vasculature, and therefore typically lead to disease 
stabilization but not regression, targeting active tumor vascular cells could potentially lead to 
tumor necrosis and disease regression.  Ovarian tumor vasculature has been demonstrated to be 
unique from normal resting vasculature (112, 181).  Several peptides have been identified and 
developed which bind with relatively high affinity and specificity to tumor vessels.  RGD 
(arginine–glycine–aspartic acid) motif containing peptides have been developed which bind to 
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integrin molecules which are up-regulated on tumor vessels and sometimes tumor cells (182, 
183).  Similarly, aspargine-glycine-arginine peptides can be used to target CD13 isoforms 
expressed in tumor vasculature (184).  The 31 amino acid F3 peptide has also been shown to 
bind to nucleolin protein expressed on the surface of tumor endothelial cells as well as on the 
surface tumor cells (185-187). 
These peptides have been used to target nanoparticles carrying various therapeutic 
payloads to the tumor, such as MRI contrast agents and photodynamic drugs (188, 189).   This 
approach allows the therapeutic agent to be concentrated at the tumor site, while reducing 
systemic exposure and potentially reducing drug related side effects.    RGD targeted cisplatin 
nanoparticles were found to inhibit endothelial cell proliferation in vitro (190). RGD targeted 
paclitaxel containing nanoparticles were demonstrated to target ovarian cancer cells in vitro and 
in vivo and effectively restrict ovarian tumor growth(191).  Similarly, in several tumor models 
including ovarian cancer, vascular targeted liposomal doxorubicin was found to be a more 
effective therapeutic than traditional doxorubicin or liposomal doxorubicin (192).  Interestingly, 
a targeting peptide (iRGD) has been developed that combines the RGD motif with a protease site 
and a neuropilin targeting motif to create a peptide that promotes trans-endothelial passage of 
nanoparticles to enhance tissue penetration and targeting to tumor cells (193).  The F3 peptide 
has also been used to deliver nanoparticles to the tumor microenvironment.  A rat model of 
glioblastoma multiforme suggested that F3 targeted nanoparticles can be used for both tumor 
imaging and tumor therapeutics (186). 
Studies to date have all focused on in vitro studies or studies in rodents.  One 
shortcoming of these studies is the lack of a demonstration of activity against human tumor 
vessels in vivo.  A model of human tumor vasculature has recently been developed (92, 93).  This 
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model uses human embryonic stem cells as a source of vascular cells, thus the vascular cells are 
human.  Vessels that are generated in this model demonstrate that they have both human 
endothelial and vascular smooth muscle cells.  
We used the F3 peptide to deliver cisplatin loaded polyacrylamide (PAA) nanoparticles 
to tumor vessels in both murine and human ovarian cancer models.  We demonstrate that these 
nanoparticles bind to murine and human tumor endothelial cells both in vitro and in vivo.  When 
used as a therapeutic, these nanoparticles lead to significant tumor regression and then 
stabilization of tumor burden.  Nanoparticles were effective in both xenograft and orthotopic 
tumor models.  Our data strongly support the efficacy of vascular targeted nanoparticle therapy 
in ovarian cancer and represent the first demonstration of chemo-nanoparticle binding to human 















MATERIALS AND METHODS 
Nanoparticle (NP) Preparation 
Chemicals 
Acrylamide, N,N,N’,N’- tetraethylmethylenediamine (TEMED), Ammonium persulfate 
(APS), Polyethylene glycol dodecyl ether (Brij 30), 3-(acryloyloxy)-2-
hydroxypropylmethacrylamide (AHM), hexane, and dioctyl sulfosuccinate (AOT) were 
purchased from Sigma Aldrich. 3-(aminopropyl) methacrylamide (APMA) was obtained from 
Polysciences Inc.and ethanol (190 proof) was obtained from Fisher Scientific. Cisplatin was 
purchased from SICOR pharmaceuticals Inc. (Irvine, CA), while Sulfosuccinimidyl 4-[N-
maleimidomethyl] cyclohexane-1-carboxylate (Sulfo-SMCC), Traut’s reagent (2-IT), amine 
reactive fluorescein isothiocyanate (FITC) and AlexaFluor 594 were from Thermo Scientific Inc. 
All solutions were prepared from 18 MΩ water purified by a Barnstead/Thermolyne Nanopure II 
system except where otherwise stated.  
   
                                                       Blank Np polymerization 
Hexane (45 mL) was added into a dried 100 mL round bottom flask and stirred under a 
constant purge of argon. AOT (1.6 g) and Brij 30 (3.1 g) were added to the reaction flask and 
stirring was continued under argon for 20 min. In the mean time, acrylamide (0.711 g) and 
APMA (0.055 g) were dissolved in PBS (pH=7.4) in a glass vial by sonication. AHM (0.428 g) 
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was added to the acrylamide solution and the reaction mixture was sonicated for 5 min to obtain 
a uniform solution. The solution was then added to the hexane reaction mixture and vigorously 
stirred for 20 min at room temperature under argon protection. Polymerization reaction was 
initiated by adding freshly prepared ammonium persulfate (10% aqueous solution, 40 µL) and 
TEMED (40 µL) and the resulting solution was stirred vigorously at room temperature overnight 
(12 hour). At the completion of polymerization, hexane was removed by rotary evaporation and 
the particles were precipitated by addition of ethanol. The surfactant and unreacted monomers 
were washed away from the particles by washing with ethanol (5×160mL) followed by washing 
with water (5×100 mL) in an Amicon ultra-filtration cell (200mL, equipped with a Biomax 
100kDa cutoff membrane). The concentrated Np were lyophilized for two days before use.  
   
                           Cisplatin-Encapsulated and FITC or AlexaFluor linked Np 
The polymerization procedures for cisplatin-encapsulated Np were the same as above 
except that 2mL cisplatin (SICOR Pharnaceuticals Inc, Irvine, California, obtained via the 
Department of Pharmacy at the University of Michigan) drug solution (1mg/mL) was used to 
dissolve all the monomers. The cisplatin-encapsulated nanoparticles were protected from light 
during the production process. An inductively coupled plasma (ICP) (Perkin-Elmer Optima 2000 
DV with Winlab software) was used to determine the concentration of cisplatin encapsulated.  
The cisplatin concentration was measured by ICP to be 0.75±0.02 ug/mg Np. The nanoparticle 
solution for each injection was prepared to allow consistent dosing of cisplatin among 
experiments. 
For fluorophore linked Np, 1mg of FITC or 5mg of AlexaFluor 594 was added into 
monomer solution and the mixture were kept stirring at 37°C for an hour before injected into 
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hexane. The rest of the procedures were same as Cisplatin encapsulated Np.  Blank, fluorophore 
conjugated, or cisplatin encapsulated PAA Np, were prepared with a final average size of 
24.4nm (polydispersity index equals to 0.120). 
   
                                                                  F3 targeted Np 
Cisplatin encapsulated (or fluorophore linked or blank) Np were suspended in PBS (pH 
7.2) solution by sonication, followed by adding suitable amount of Sulfo-SMCC. After half an 
hour reaction under stirring, the SMCC conjugated Np were washed by using Amicon centrifugal 
filter unit for 3 times. Prescribed amount of F3 peptide and 2-IT was dissolved in DI water under 
stirring for 2 hours at 37°C, and was added into the SMCC conjugated Np suspension. The 
mixture was stirred at room temperature overnight and then washed again to obtain the 
concentrated Np. 
 
                                                                 In vitro Studies 
ID8, SKOV3, A2008 cells were a generous gift from Dr. George Coukos and A2780 
ovarian cancer cell lines were a generous gift of Dr. Rebecca Liu.  Tumor endothelial cells 
(TEC’s) were freshly generated from VE-Cadherin+/CD146+ cells FACS isolated from 
mechanically dissected tumors as previously described (194, 195). TEC were then grown in 
EBM2 media (Clonetech).  Monocytes were isolated from 2ml of donor blood based upon their 
ability to adhere to plastic following ACK lysis.  All cells except TEC were grown in 
RPMI/10%FBS/5% penicillin-streptomycin, medium and split two days prior to experiments to 
40% confluency.   For binding experiments, cells were incubated with a range of F3 targeted 
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AlexaFluor 594 linked Np (F3-Alex-Np), or blank Np (10-100 mg/ml) for 4 hours with 
intermittent rocking. Cells were then washed three times with PBS under sterile conditions and 
returned to the incubator for 30 minutes and then imaged using a Nikon fluorescent microscope 
(Nikon) attached to CoolSNAP CCD camera (Roper Scientific).  In order to determine in vitro 
killing efficiency cells were incubated with F3 targeted blank Np (F3-Np), F3 targeted cisplatin 
encapsulated Np (F3-Cis-Np, 0.15 µg/ml final cisplatin concentration), parental cisplatin 
compound (at 5µg/ml final concentration for cell line experiments and at 1 ug/ml for TEC and 
PBMC experiment) or mock treated with PBS.  The cells were washed after 4 hours and then 
allowed to grow for a total of 72 hours prior to harvesting for cell counting via trypan blue 
exclusion. 
Mouse Studies 
  All mice were housed at the University of Michigan Medical School in the Unit for 
Laboratory Medicine (ULAM) and protocols were approved under the University Committee on 
the Use and Care of Animals (UCUCA). Tumor cell lines were grown in DMEM/10%FBS/5% 
penicillin-streptomycin, medium.  
Axillary and flank tumor models: 10x106 cells were injected with 0.2 ml of PBS and 
300ul of matrigel (BD Biosciences).  In the initial targeting experiments, axillary tumors were 
allowed to grow for 10 days and then 100 mg/Kg F3 targeted Alexa-488 linked Np (F3-FITC-
Np) or Alexa-488 linked Np (FITC-Np, ) were administered intravenously. 24 hr after injection 
the mice were sacrificed and tumors, liver, lung, kidney, heart and spleen were harvested and 
examined for fluorescent nanoparticle uptake.  For therapeutic studies Hey1 tumor cells were 
stably transduced with a DsRed expressing lentivirus (plentiloxEV-DsRed virus, provided by the 
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vector core at the University of Michigan).  Tumor cells were injected subcutaneously into either 
the flank (ID8 studies) or axilla (SKOV3, A2780-GFP, and DsRED HEY1) of either C57Bl6 or 
nu/nu mice respectively.  Axillary injection was used in the case of the human tumor xenografts 
as we find axillary tumors have a greater microvascular density than flank tumors.  Xenografts 
were allowed to establish as indicated and were treated with either (1) IP cisplatin at 250 µg/kg 
alone or (2) IP cisplatin combined with with F3-Np via tail vein injection or (3) with F3-Cis-Np 
via tail vein injection (IV) at 100mg/kg of nanoparticles (final cisplatin concentration 75 µg/kg).  
Mice were treated initially at Day 10 and Day 14 (all tumor xenografts) and Day 21 (for ID8 and 
SKOV3 xenografts only). Tumor volume was monitored via caliper (W2 x L/2). A2780-GFP 
mice were imaged with whole body imaging utilizing the Maestro imaging system. Mice were 
sacrificed on either day 18 or day 28.  Axillary and flank tumors were harvested for histology 
and immunohistochemistry. 
Intraperitoneal (IP) models:  Mice were randomized by weight to the various treatment 
groups for IP injections. 2.0 x106 ID8 cells harvested in exponential growth were injected 
intraperitoneally in 0.2 ml of PBS.  Tumor cells were then allowed to grow for 10 days prior to 
first treatment.  Control mice were then treated with either IP cisplatin at 250 µg/kg alone or 
along with (1) IP blank F3-Np, (2) IV blank F3-Np, or (3) both IP and IV administered blank F3-
Np.  Alternatively mice were treated with F3-Cis-NP (1) delivered IV, (2) IP, or (3) both IV and 
IP.  Nanoparticles were dosed with final cisplatin does of 150 µg/kg; 150 µg/kg for IV or IP 
alone, or 75 µg/kg IV and 75 µg/kg IP for IV/IP treated animals.  Mice were treated at days 10, 
14, 21 and 28.  Mice were followed for weight gain/ascites and sacrificed after a 10 gram weight 
gain or when they appeared moribund.  Kaplan-Meier curves were plotted and statistical analysis 
performed via log rank test. 
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Teratoma Model:  Hey-1/teratomas were generated as previously described (92, 93).  
Briefly, H9 embryonic stem cells (ESC) were cultured on mouse embryonic fibroblasts, 
manually dispersed, and passaged.  1x106 undifferentiated H9 embryonic stem cells were 
injected subcutaneously into the axilla of NOD-SCID mice with matrigel and allowed to grow 
until teratomas were palpable.  100,000 DsRed-HEY1 cells were then injected within teratoma.  
Tumors were imaged using bio-immunofluorescence.  Given the large size of the 
tumor/teratomas and their rapid growth rates, mice were then treated with intravenous F3-Np or 
F3-Cis-Np 75µg/kg every 48 hour, 4 times, for a total of 8 days.  Tumors were harvested 24 
hours after the 4th NP treatment.  Controls were treated with F3-FITC-Np 1 hour prior to 
sacrifice to confirm F3-NP targeting to human vessels. Tumors were then analyzed with Co-IF 













Targeting of F3-targeted nanoparticles to tumor endothelial cells and tumor cells in vitro 
  Blank, fluorophore conjugated or cisplatin encapsulated PAA Np, were prepared with a 
final average size ranging from 20-30 nm (Figure A1). The PAA nanoparticle is a hydrogel that 
has a high aqueous solubility and long plasma circulation time, being suitable for in vivo 
applications (186, 188, 196). It also has excellent engineerability within both nanoparticle core 
and surface, which allowed conjugation of fluorophores and/or multiple targeting/visualization 
peptides for the current studies.  F3 peptide was conjugated to the Np for targeting.  This peptide 
is a subcomponent of the HMGN2 protein and has demonstrated specificity for both human 
tumor cells and vasculature (185-187).   Alexafluor-594 was bound to the nanoparticles (Alex-
Np) for visualization in initial targeting experiments. To test the ability of the F3 peptide to 
target ovarian tumor cells, both mouse and human ovarian cancer lines (Mouse ID8 and Human 
SKOV3, A2008, A2780) were incubated with either F3-Alex-Np (100µg/ml) or Alex-Np 
(1mg/ml).  We observed significant binding of the F3 targeted Np to all ovarian tumor cell lines 
tested (Figure A2A).  Little or no binding was observed with Np that lacked the targeting F3 
peptide.  We next tested the ability of F3-Np to bind to tumor endothelial cells (TECs) (Figure 
A2A).  F3-Alex-Np demonstrated strong binding to both mouse and human TECs.  Once again, 




In vitro cytotoxicity of F3 targeted cisplatin encapsulated Np: 
In order to determine the cytotoxic potential of F3 targeted Np, tumor cell lines were 
treated with either PBS, F3-Cis-Np, blank F3-Np combined with cisplatin, for four hours and 
then washed.  The final concentration of cisplatin in the F3-Cis-Np was 0.15 µg/ml and that of 
cisplatin combined with the blank F3-Np was 1 µg/ml for TEC/PBMC experiments and 5 µg/ml 
for A2780 and SKOV3 experiments.  The cells were then allowed to grow for an additional 72 
hours and harvested.  We then assayed the number of viable cells in each treatment group 
relative to the PBS control.  Consistent with previous studies of nanoparticles targeting tumor 
cells, our experiments demonstrated little cell death in the nanoparticle experimental groups 
(Figure A2B) (197-199).   
We then repeated these experiments using tumor endothelial cells isolated from both 
murine ID8-VEGF ovarian tumors and human ovarian cancers.  Unlike what was observed for 
the tumor cell lines, we observed significant induction of cell death with F3-Cis-Np on both 
mouse and human tumor endothelial cells.  No cell death was noted when treating control 
PBMCs (Figure A2B).  Thus F3 targeted Np appear to be more toxic to tumor endothelial cells 
than to tumor cell lines. 
 
F3 –Np target tumor vessels in vivo 
To test the efficacy of F3 targeting in vivo we used the highly vascular ID8-VEGF 
ovarian tumors model (200).  Mice bearing ID8-VEGF tumors were treated intravenously with 
increasing concentrations of either non-targeted Alexa488-Np or F3 targeted Alexa488 Np.  
Mice were sacrificed 24 hours after infusion and multiple tissue and tumor specimens were 
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harvested and examined via fluorescence for nanoparticle localization.  Highest specific binding 
to tumor vessels without significant uptake in liver and kidney was determined at a dose of 
100mg/kg (range tested 25-200 mg/kg, Figure 2C and data not shown).  At this dose, non-
targeted FITC-Np demonstrated little tumor specific uptake, but were found at significant levels 
in the liver and kidney.  In contrast, at this concentration we observed significant uptake of F3-
FITC-Np in tumor vessels and some uptake within tumor parenchyma.  We noted minimal 
uptake of F3-FITC-Np in kupffer cells of the liver and within the renal collecting tubules (Figure 
A2C and data not shown). No significant binding was observed in other tissues including the 
lung, heart, spleen, intestine, or brain (data not shown).  
 
Therapeutic efficacy of F3-Cis-Np 
Next, to test the therapeutic efficacy of the nanoparticles, ID8-VEGF tumors were grown 
in the axillas of mice for 14 days.  Mice were then treated intravenously with two weekly doses 
of F3-Cis-NPs, with a final cisplatin concentration of 70 µg/kg, IP cisplatin at 250 µg/kg or IP 
cisplatin at 250 µg/kg, combined with intravenous blank F3-NPs (total n= 15 for cisplatin or 
cisplatin and F3-Np and n=20 for F3-Cis-Np in two independent experiments) and then 
sacrificed one week later.  Following the initial administration of F3-Cis-Np we observed a rapid 
and significant decline in tumor volume.  This was maintained throughout the experiment.  IP 
cisplatin alone and IP cisplatin/IV F3-NPs yielded identical results (data not shown).  At the 
conclusion of the experiment, a 2.5 fold reduction in overall weight of the tumors and ~3.5 fold 
reduction in volume were noted when compared to IP cisplatin alone or IP cisplatin/IV F3-NPs 
(Figure 3A and data not shown). Histological analysis of these tumors demonstrated (1) large 
	  
118	  
regions of hemorrhage and necrosis consistent with a potent anti-vascular effect and (2) a 
significant reduction in the size of tumor islets with an increase in stromal tissues (Figure A3B). 
In order to determine the potential toxicity of this therapy, we collected serum from 3 
animals in each treatment group 24 hours after the last intravenous treatment.  Serum creatinine 
(a marker of renal function), aspartate aminotransferase and alanine aminotransferase (markers 
of hepatic function) and complete blood counts were not significantly different among untreated 
and F3-Cis-NP treated mice (Figure A3C).  This suggests these Np are not excessively toxic to 
normal tissues.  Further supporting the safety of the Np, unlike mice treated with systemic 
cisplatin, we observed no significant weight loss for F3-Cis-Np treated mice nor any other 
adverse effects (data not shown). 
 We next tested the impact of Np on tumor growth using an orthotopic intraperitoneal 
tumor model.  Tumors were allowed to engraft for 10 days and then mice were treated with 
either IP cisplatin at 250 µg/kg along and F3-Np IV, IP cisplatin alone, or F3-Cis-Np IV with a 
final concentration of 75ug/kg cisplatin.  We observed a significant increase in the overall 
survival of animals treated with the F3-Cis-Np as compared to IP cisplatin alone or along with 
F3-NPs (Figure A3D(1) and data not shown).  To determine if combining IV F3-Cis-Np with IP 
F3-Cis-Np therapy could improve survival further by targeting both tumor vasculature (via IV 
dosing) and tumor cells (via IP dosing), we repeated the orthotopic tumor studies and compared 
various combinations of Blank F3-Np and cisplatin delivered IV, IP or combined IP and IV 
versus F3-Cis-Np via IV, IP, or IV and IP administration at 150 µg/kg (for IV or IP alone) or 75 
µg/kg for the both IV and IP treatments for a total cisplatin concentration of 150 µg/kg.  Mice 
were treated on days 10, 14, 21 and 28.  We observed a significant survival advantage for all 
groups which received F3-Cis-Np intravenously as compared to mice receiving blank F3-Np 
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combined with cisplatin.  Interestingly, combined IV and IP treatment with F3-Cis-Np did not 
show a significant difference in survival (Figure A3D).  This suggest that vascular exposure is 
the primary means of therapy as the addition of intraperitoneal therapy which could directly 
target tumor cells, had no added benefit. 
We also tested the impact of F3-Cis-Nps using subcutaneous human tumor cell line 
xenograft tumor models.  We used cisplatin sensitive Hey1, and cisplatin resistant A2780-GFP 
cells (IC50 7mM) and SKOV3 (IC50 4mM) ovarian tumor cell lines (n=11 in treatment and 
control groups). As the human tumor xenografts with Hey1 and A2780 cells grow more rapidly 
than ID8 cells we used a more frequent treatment schedule, treating mice on Days 7, 10, and 14 
after tumor engraftment with either F3-Cis-Np or blank Np and systemic cisplatin as described 
above.  In the platinum sensitive Hey1 and A2780-GFP tumors there was clear arrest of tumor 
growth during the course of therapy as indicated both by tumor volumes and in vivo 
biofluorescent imaging (Figure A4A, B and data not shown).  Consistent with an antivascular 
effect rather than an anti-tumor effect, we observed a similar growth arrest with therapy of the 
platinum resistant SKOV3 tumors.  Also consistent with a loss of tumor vascular perfusion, 
tumors resected from these mice were extremely pale compared to controls (Figure A4B).   
Histochemical analysis of tumors demonstrated a significant loss reduction in microvasculature 
the F3-Cis-Np treated mice and significant tumor necrosis similar to that observed with the ID8 






F3-Cis-Np target and eliminate human tumor vessels in vivo 
Finally, as we demonstrated that the F3 targeted Np were capable of binding to human 
tumor endothelial cells in vitro, we wished to determine if the Np could bind to human tumor 
vessels in vivo.  In order to test this we used a recently developed model of human tumor 
vasculature which utilizes Hey1 tumors cells injected into H9 ESC derived teratomas.  In this 
model tumor vascular cells are derived from the human ESC and thus are human in origin.  We 
performed intravenous injections of F3-Alexa-Np in H9-ESC-Hey1 tumor bearing mice.   
Importantly, we observed clear binding of the F3-Alexa-Np to the human CD31+ tumor vessels, 
confirming the ability of these F3 targeted Np to bind to human vessels in vivo.  We therefore 
used this model to test the therapeutic efficacy of F3-Cis-Nps.  To track tumor cell growth we 
used immunofluorescent DsRED Hey1 tumor cells.  Once again we treated animals with either 
IV F3-Np and systemic cisplatin or F3-Cis-Np (n=3 controls and n=3 treatment groups in two 
independent experiments).  Animals were treated on day 10, 14, 17 and 21.  Like the previous 
tumor models, treatment with F3-Cis-Np lead to an initial loss of fluorescence and then 
stabilization of disease, whereas tumors treated with systemic cisplatin demonstrated progressive 









In this study, we used an F3-targeted polymeric nanoparticle formulation consisting of 
encapsulated cisplatin in a polyacrylamide nanoparticle to target tumor vessels as a cancer 
therapeutic.  While vascular targeted nanoparticle studies have been reported previously, to our 
knowledge ours is the first to demonstrate the ability to bind to human tumor vessels in vivo.  
F3-Cis-Np therapy appeared safe with minimal side effects.   In vitro studies 
demonstrated specific binding to tumor and tumor endothelial cells.   In vivo studies also 
demonstrated predominant binding to microvascular tumor endothelial cells with lesser uptake 
on tumor cells.  We observed some minimal non-specific uptake in kupffer cells of the liver and 
nanoparticles were excreted via the kidneys.  However, non-specific binding was minimized with 
titration of dose and minimal toxicity was noted with F3-Cis-Np treatment as evidenced by stable 
creatinine, liver function tests and complete blood counts.  This is not surprising given the total 
cisplatin dose used in the nanoparticle studies (75 or 150 mg/Kg) was ~1/20th the traditional dose 
of cisplatin (1-5mg/kg).   
In addition to being safe, F3-targeted nanoparticles appear to be a highly effective as a 
therapeutic.  While F3 peptides can bind both tumor cells and endothelial cells, our studies 
suggest that the primary effect of therapy was anti-vascular: Similar to prior studies, minimal in 
vitro cytotoxicity was noted with F3-Cis-Np treatment of human tumor cell lines (197-199). This 
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may be  due to the higher concentration of drug needed to kill tumor cells as evidenced by their 
higher IC50.  In contrast we observed significant in vitro cytotoxicity of F3-Cis-Np on human 
tumor endothelial cells (Figure 2C).  In addition we observed a rapid impact of therapy, 
associated with large regions of necrosis and hemorrhage, and a loss of clearly defined 
microvasculature consistent with an anti-vascular effect.  Moreover, F3-Cis-Np were effective 
even in cisplatin resistant tumors.  Finally, like other anti-angiogenics, continuous treatment was 
associated with stable disease and no further reduction of tumor was noted. 
F3-Cis-Np therapy was effective in both solid tumor and IP tumor models.  While the 
impact of therapy on flank tumors was most dramatic, a clear survival advantage was noted in 
the IP tumor model.  The survival advantage was primarily associated with IV treatment.  
Interestingly, the combination of both IP and IV nanoparticles did not demonstrate a clear 
advantage over IV only nanoparticles.  This may be because the cisplatin dose in the F3-Cis-Nps 
is sub-therapeutic to kill tumor cells as observed in vivo.  Alternatively, while we did not see 
significant systemic Np exposure with IP delivery (data not shown), it is possible the Np 
delivered IP are still primarily taken up in the tumor vasculature.  
We speculate that anti-vascular cell therapy may be much more effective clinically than 
specific molecular biologic anti-angiogenic therapies; resistance to therapies targeting specific 
molecular pathways can develop through the up-regulation of one of numerous redundant 
angiogenic pathways.  However, the endothelial cell is the final target of all angiogenic 
pathways, thus elimination of the endothelial cell should inhibit all of these angiogenic 
pathways.     
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Based on previous observations that F3 peptide can target tumor cells, we chose to load 
our nanoparticles with cisplatinum, the most active anti-ovarian tumor cell agent.  Given our 
observations that the F3 targeted nanoparticles appear to be primarily targeting tumor vascular 
cells, cisplatin may not be the most active chemotherapeutic.  Cisplatin is a DNA targeting agent 
and is most active against actively proliferating cells; more established non-dividing vascular 
cells would be less sensitive to this agent.  This would explain the stable disease we observed 
with repeat therapy.  We hypothesize that therapy with a microtubule targeting agent, such as the 
taxanes, may demonstrate even greater activity.  Furthermore, an iRGD peptide was recently 
described (193).  This peptide targets the vasculature and is then cleaved to allow release of the 
peptide with a now exposed neuropilin-1 binding motif which mediates penetration of the 
peptide through the vasculature to target tumor cells.  Thus a combination of F3-Taxane 
nanoparticle and iRGD peptide targeted cisplatin nanoparticles could be particularly effective—
targeting neo-vasculature, established tumor vessels, and tumor cells.  Given the extremely low 
doses of chemotherapeutic agents necessary for effectiveness of the Np as demonstrated in the 
current study, such a combination could be possible with an acceptable side effect profile.  
Further experiments will be necessary to determine the appropriate sequencing for combining 
these agents; vascular disruption prior to the administration of anti-tumor agents could in theory 
reduce intratumoral drug delivery and thereby reduce efficacy.  In this context, dynamic imaging 
studies may be useful also to address the optimal schedule of administration of combination 
therapies.   
  Finally, we show for the first time, the ability of vascular targeted Np to effectively 
target human tumor endothelial cells, not only in vitro, but more importantly in vivo.   We used a 
human ESC based tumor model in which a subset of the tumor vascular cells are derived from 
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the human ESC and are therefore human tumor vessels (93).  We have demonstrated that the 
vessels in this model are indeed tumor vessels, expressing unique tumor vascular markers (201).  
Thus we believe that this model represents an excellent tool for the study of therapeutics 
targeting human tumor vasculature.   
In conclusion we have demonstrated that F3-targeted nanoparticles are a safe and 
potently effective anti-vascular therapeutic. Activity appears primarily due to the elimination of 
tumor microvasculature.  This proof of principle study demonstrates the ability to overcome 
ovarian cancer chemoresistance using vastly reduced drug concentrations by targeting 
nanoplatforms to the tumor neovasculature/microenvironment. Importantly, we demonstrate that 
these nanoparticles are effective in binding and eliminating human tumor endothelial cells.  
These preclinical studies indicate that further anti-vascular study in human tumors is warranted. 
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Figure A1.  Development of nanoparticles.  A Schematic demonstration of the production of 
both blank and cisplatin containing F3 targeted nanoparticles. B.  The scanning electron 







Figure A2. Binding and cytotoxicity of F3 targeted nanoparticles.  A.  In vitro binding of 
fluorescent nanoparticles demonstrating effective binding of F3 targeted Alexa-594 nanoparticles 
(F3-Alexa-Np) but not for non-targeted Alexa-594 control nanoparticles (Alexa-Np)  to murine 
and human tumor endothelial cells (mTEC and hTEC) and murine (ID8) and human (SKOV3) 
tumor cell lines.  B. Percent viable cells (relative to PBS controls) following treatment with F3-
Cis-Np, blank F3 targeted nanoparticles (F3-Np), or cisplatin (1 mg/ml for TECs and 5mg/ml for 
tumor cells) targeting human tumor endothelial cells (TEC), human peripheral blood monocytes, 
and ovarian tumor cells (SKOV3 and A2780). C.  In vivo binding of F3-Alexa488-Np and non-






Figure A3. Therapeutic efficacy and toxicity of F3-Cisplatin-nanoparticles in a murine 
ovarian tumor model. A.  Tumor growth curves and weights of ID8 xenografts treated with F3-
Cis-Np or blank F3-Np and systemic cisplatin (n=15 animals per group).  Arrows indicate time 
of treatment.  B.  Tissue histology of tumors from control animals treated with blank F3-Np and 
systemic cisplatin (F3-Np + Cis) or F3-Cis-Np.  Low power image demonstrates large area 
	  
129	  
ofvascular necrosis (upper right) in treated tumors.  High power images demonstrate significant 
reductions in tumor islets in treated tumors (lower right).  C.  Lack of toxicity in F3-Cis-Np 
treated animals as demonstrated alanine aminotranferease (ALT) and aspartate aminotransferase 
(AST), blood urea nitrogen (BUN) and serum creatinine from mice treated with F3-Cis-Nps or 
F3-Np controls.  Normal ranges are indicated (parentheses).  D.  Kaplan Meier curves indicating 
survival using an orthotopic intraperitoneal tumor model (1) comparing intravenous (IV) F3-Cis-
Np vs IV control nanoparticles + systemic cisplatin delivered intraperitoneally (F3-Np + Cis), 
and (2) comparison of indicated treatment groups comparing IV and IP treatment of F3-Cis-Np 
and various controls.  Greatest survival advantage was seen in the IV F3-Cis-Np group.  
Addition of IP F3-Cis-Np added no survival advantage (n=10 animals per group).  Arrows 











Figure A4. Therapeutic efficacy of F3-Cis-Np against human tumor xenografts.  A.  (1) 
Tumor growth curves and (2) in vivo fluorescent imaging of control (F3-NP and IP cisplatin 
treated) and F3-Cis-Np treated A2780 cisplatin sensitive tumor xenografts.  B (1) and (2).  
Tumor growth curves and gross tumor pathology of F3-Cis-Np treated and control F3-Np and IP 
cisplatin (F3-Np + Cis) treated cisplatin resistant SKOV3 tumor xenografts.  F3-Cis-Np treated 






Figure A5. F3 targeted Np effectively target human tumor vessel s in vivo.  A. 
Immunofluorescence demonstrating the F3 targeted Alexa488-Np (F3-Alexa-Np) bind to human 
CD31+ (hCD31) vessels in vivo using a human embryonic stem cell tumor model with human 
vessels.  Red arrow indicates hCD31+ human vessel.  White arrows identify hCD31(-) murine 
vessels.  B.  In vivo fluorescent imaging of F3-Cis-Np and control (blank F3-Np) treated ESC-
DsREd Hey1 tumors just prior to the first IV treatments (day 8) and at the time of sacrifice two 
days after the last IV treatment (day 16).  C. Tumor growth curves of F3-Cis-Np treated and 
control (F3-Np) treated ESC-DsREd Hey1 tumors with human tumor vessels.  Arrows indicate 
times of IV NP treatments (n=3 per group in two independent experiments).  D.  Tumor weight 
and density of human vessels in F3-Cis-Np treated and control (F3-Np) treated ESC-DsREd 
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